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3FOREWORD 
Animal research is currently essential for the 
development of new and safe medicines, and the 
UK is a world leader in this regard. In the future, 
in vivo education and training will be vital if the 
UK is to remain at the forefront in championing 
standards and best practice internationally, as well 
as attracting global biomedical research.
On behalf of the British Pharmacological Society, 
I am pleased how ambitious and forward-thinking 
the evaluation of the Integrative Pharmacology 
Fund has proven to be – in keeping with the spirit 
in which funding was originally launched in 2004. 
Many thanks to the report’s evaluation team for 
developing such targeted, specific and realistic 
recommendations, and to the many individuals 
who participated and provided feedback during the 
course of this important project. 
The British Pharmacological Society is proud to 
be a leader in the in vivo sciences, both in terms of 
driving long-term collaborative, cross-discipline 
partnerships and providing funding where 
appropriate. However, the Society is also mindful of 
the important contributions of other organisations 
and networks with an interest and a role in the future 
of in vivo education, training and research. The 
Society supports the recommendations made in this 
evaluation and will commit resource to exploring 
their implementation with the wider community.  
If you identify any further opportunities as you 
consider the evaluation’s findings, you are invited 
to get in touch with the Society’s Education Team at 
education@bps.ac.uk
Professor David Webb MD 
DSc FRSE FMedSci FBPhS 
President, British 
Pharmacological Society
4CONTENTS
EXECUTIVE SUMMARY 5 
1. INTRODUCTION 8
2. THE INTEGRATIVE PHARMACOLOGY FUND 9
 2.1. Background and aims 9
 2.2. Current landscape 11
3. METHODS AND EVALUATIVE CRITERIA 13
 3.1.  Methods 13
 3.2.  Evaluative criteria 14
4. THE INTEGRATIVE PHARMACOLOGY FUND OUTCOMES 16
 4.1. Community capacity 16
 4.2.  Career development 19
 4.3.  Research practice and outcomes 23
 4.4.  Network, collaboration, dissemination 24
5. RECOMMENDATIONS 27
APPENDICES 37
 Appendix 1 – The Steering Committees 37
 Appendix 2 – List of acronyms 38
5EXECUTIVE SUMMARY
This report is the product of an evaluation of the Integrative 
Pharmacology Fund (IPF) conducted by the British Pharmacological 
Society in collaboration with the University of Exeter between October 
2015 and July 2016. The purpose of the evaluation was to identify the 
outcomes of the IPF and assess the extent to which it has supported 
sustainable solutions to the in vivo skills gap, in the context of a 
changing landscape for the demands and delivery of in vivo research. 
The IPF was launched in 2004 to sustain the capacity 
for in vivo education, training and research in higher 
education, and to foster improvements to animal welfare, 
the 3Rs (replacement, reduction and refinement of the 
use of animals in research) and research outcomes. In this 
report, we evaluate the outcomes of the IPF against the 
following criteria: 
  To what extent has the IPF contributed to improving 
community capacity for in vivo education, training 
and research? 
  To what extent has the IPF contributed to individual 
career development? 
  To what extent has the IPF contributed enhancements 
to research practice and outcomes?
  To what extent has the IPF contributed to development 
of research networks, dissemination and collaboration?
The findings of this report are based on quantitative and 
qualitative analyses. A quantitative survey was used to 
compile key metrics concerning the use of in vivo skills in 
the subsequent careers of undergraduates, postgraduates 
and postdoctoral researchers who received IPF-funded 
education, training or grants. Data were also compiled 
from undergraduate end of module/course evaluations. 
In-depth qualitative interviews were then conducted with 
participants involved in different strands of the IPF-funded 
activities, in order to acquire a fine-grained understanding 
of the local impacts of the IPF intervention, compare 
research needs, organisational contexts and requirements 
in relation to in vivo training across institutions and groups, 
and identify ways forward for the future.
The key findings of the evaluation are as follows:
  The IPF initiative successfully increased the capacity 
of in vivo education, training and research in academic 
institutions, at least partially off-setting projected 
losses due to retirement;
  There are enduring concerns about the retention of in 
vivo skills and how best to build sustainability through 
local investments in people with those skills;
  The careers of those supported by the IPF continue to 
benefit from the support received, with notable levels 
of follow-on grant success, collaborative network-
building and growth in personal reputations;
  The education and training received by students was 
of high quality, and contained substantial material on 
experimental design, animal welfare and the 3Rs;
  The in vivo researchers appointed as a result of the 
IPF have enabled colleagues who are not in vivo 
scientists to pursue new lines of research, including 
some of a more translational nature;
  The Integrative Mammalian Biology (IMB) centres 
were strong local networks of researchers and 
students that helped foster collaborations and the 
sharing of current good practice;
  The the Experimental Officer role at The University  
of Manchester provides a novel and successful 
model for skills retention, training, monitoring of 
animal welfare, forging collaborations and sharing of 
current good practice. 
The report makes recommendations on how in vivo 
research skills in the UK can be best supported in the 
future, drawing lessons from the implementation 
and impact of the IPF. These recommendations are 
summarised here, accompanied by key principles that 
emerged from the evaluation and which should inform 
future initiatives and their conduct. Throughout the 
evaluation section, we have identified recommendations 
that derive from the conclusions we reached. At the end, 
there is a detailed examination of each recommendation, 
and the further steps we propose to work towards 
fulfilling them. 
The recommendations build upon the lessons learned 
from the evaluation to suggest efficient methods of 
assessing and conducting in vivo training and education, 
and fostering new collaborations and the adoption of 
good practice. Reflecting on the model of the IPF itself, 
we make proposals based upon a partnership approach 
to funding, coordination and delivery. Potential partners 
are suggested but other organisations or individuals are 
invited to contribute.
The recommendations comprise a mix of proposals 
that can be easily achieved in the short term, proposals 
that depend on the development of partnerships 
and initiatives and will bear fruit on a medium-term 
timescale, and proposals for the long term. The 
recommendations listed here are discussed in full in 
Section 5. 
61.  Develop core learning outcomes. Educators and 
employers in the in vivo community should work 
together and lead the development of clear core 
learning objectives for the in vivo sciences, including 
experimental design, statistics, animal welfare, 
cultures of care, ethics and the 3Rs. These outcomes 
should be integrated across the biosciences, 
and should be reinforced throughout a student’s 
undergraduate and postgraduate career. 
2.  Conduct research on educational outcomes. Higher 
education institutions and learned societies should 
conduct research on the educational outcomes of 
different education and training routes and methods, 
and should forge ways to ensure that data collection 
and analysis are supported and based on common 
standards.
3.  Support undergraduate education modules. The 
British Pharmacological Society should continue to 
provide part-funding for undergraduate education 
modules, to foster stability and security for the 
continuation of entry-level in vivo skills education. 
4.  Create innovative resources and approaches. The 
community of educators and educational institutions 
should cooperate towards developing innovative 
education and training resources and approaches to 
prepare students for postgraduate research and/or 
employment. These approaches and resources should 
be developed in alignment with agreed learning 
outcomes and set up with impact assessment in mind.
5.  Nurture networks of good practice. The in vivo 
sciences cross a range of disciplines, and networks of 
good practice should be cross-cutting but deal with 
specific areas of need: 
   Higher education institutions, employers and 
learned societies should build and/or encourage 
participation in in vivo research and education 
networks, signposting them to people first as 
undergraduates and then throughout their 
careers. 
   Higher education institutions, learned societies 
and other relevant organisations should 
encourage and support the development of 
online open access repositories to collect and 
showcase course materials that use innovative 
approaches to learning in in vivo pharmacology. 
   National knowledge-sharing networks sharing 
good practice to advance excellent research with 
high welfare standards should be maintained 
and developed by the research community. This 
should be aided by individual higher education 
institutions, networks of and between named 
persons and other relevant individuals, the 
National Centre for the 3Rs (NC3Rs) and learned 
and professional societies. 
   Learned societies and partners should make 
grants available to support PhD students 
learning a particular in vivo technique in another 
laboratory. 
6. Provide support for early career researchers. 
   Learned societies and partners should make 
a new strategic commitment to fund pump-
priming grants for early career researchers. Such 
grants would support the development of new 
or adapted animal models and techniques to 
advance standards of animal welfare, the 3Rs, 
make research more potentially translatable, and 
provide data that recipients can use to apply for 
further grants.
   Higher education institutions, research councils, 
learned and professional societies should 
recognise the importance of explicitly in vivo 
research fellowships, and should work together 
to ensure that these positions can be financially 
supported and sustained.
7.   Support integrated pathways for technicians 
and animal technologists. There should be strong 
institutional support for career progression, skills 
training and job security for technicians and animal 
technologists, which takes account of their key 
roles in laboratory animal research. Laboratory 
animal technologists should be more integrated 
into the planning and conduct of academic research 
and preclinical research and development, both in 
industry and academic research. 
8.  Establish apprenticeships for in vivo sciences. Higher 
education institutions, the British Pharmacological 
Society, the Association of the British Pharmaceutical 
Industry, and industrial and clinical partners should 
collaborate in the development of pharmacology 
apprenticeships, including degree apprenticeships. 
9.  Foster collaborations across academia, industry and 
the NHS. Research collaborations involving in vivo 
researchers in academia, industry and the NHS need to 
be supported, with obstacles to cooperation identified 
and addressed. Academics, higher education 
institutions and industry should work together, 
supported where appropriate by research councils 
and learned and professional societies, to conduct 
studies and evaluations to inform and facilitate long-
term links, collaborations and relationships between 
academic education, training and research, industry 
and the NHS.
10.  Recognise and support engagement work. Public 
engagement and student outreach should be 
supported and encouraged by higher education 
institutions and learned societies as a core activity of 
academic researchers, advancing the commitments 
contained in the Concordat on Openness on Animal 
Research.
7From the findings of the evaluation and related recommendations,  
we have extracted four common principles to underpin future work  
and initiatives: 
Lessons from the IPF: guiding principles for future initiatives
Responsive leadership
Recognising that organisations, 
including the British Pharmacological 
Society and partners, need to take 
flexible and responsive leadership 
roles in facilitating community 
engagement, brokering resources 
and taking a long-term view of  
in vivo skills needs.
Embedded partnerships
Ensuring that long-term 
collaborative relationships 
are built between academic 
researchers and research 
institutions and researchers and 
institutions operating outside 
of academia, for instance in 
industry or the NHS.
Open pathways
Building collaborative and 
sustainable ways of working that 
recognise, value, develop and use 
the diverse routes and roles to 
and within in vivo research. 
Networked communities
Creating connected  
communities of educators  
and shared educational  
resources for good practice  
in in vivo research. 
81. INTRODUCTION
This report evaluates the outcomes of the Integrative Pharmacology 
Fund (IPF), which was launched by the British Pharmacological Society 
and partners in 2004 in response to concerns about the shortage of 
scientists with the skills and expertise to conduct in vivo research  
using mammals. 
This problem had been highlighted by skills 
surveys conducted by the Association of the British 
Pharmaceutical Industry (ABPI) and the Biosciences 
Federation.1 A survey by the British Pharmacological 
Society and The Physiological Society demonstrated 
that fewer than 2% of graduates of relevant biological 
sciences received any in vivo education in the UK, while 
25% of the academic staff qualified to provide this 
education and training were due to retire within five 
years.2 As the IPF drew to a close, an evaluation was 
commissioned by the British Pharmacological Society 
in order to assess the outcomes of the scheme. The 
evaluation was carried out by a joint project team from 
the British Pharmacological Society and The University of 
Exeter (see the inside front cover for full details).
The aim of this report is to evaluate the IPF and use the 
results of the evaluation to inform recommendations 
for the future, targeted at a variety of stakeholders. The 
report is structured as follows. First we introduce the 
history and initial aims of the IPF, contextualising these 
through discussion of the current landscape of in vivo 
education, training and research. Section 3 describes 
the methods used and outline the criteria with which we 
have assessed the outcomes of the IPF. Section 4 details 
the empirical findings on the IPF that are pertinent to 
each of these criteria. We use these results to inform 
the recommendations that are summarised throughout 
the evaluation section. The final section focuses on 
recommendations for supporting teaching and learning 
of in vivo skills and in vivo research itself in the future. 
1  ABPI and Biosciences Federation (2007) In vivo sciences in the UK: 
sustaining the supply of the skills in the 21st century. Available online 
at: http://www.abpi.org.uk/our-work/library/industry/documents/in-
vivo-report.pdf. See also: ABPI (2005) Sustaining the Skills Pipeline in the 
pharmaceutical and biopharmaceutical industries. Available online at: 
http://careers.abpi.org.uk/your-career/undergraduates/Documents/_
publications_pdfs_2005-STEM-Ed-Skills-TF-Report.pdf ; and ABPI (2008) 
Skills Needs for Biomedical Research: Creating the Pools of Talent to Win 
the Innovation Race. Available online at: http://www.abpi.org.uk/our-
work/library/industry/Documents/skills-biomedical-research.pdf
2 British Pharmacological Society (2004) A survey of integrative 
physiology/pharmacology teaching undertaken by the BPS 
and The Physiological Society, pA2 Online Vol. 3 No. 2: 10–11. 
Available online at: http://www.pa2online.org/articles/article.
jsp?volume=5&issue=2&article=31 (Note that ‘in vivo education’ here 
involved practical work conducted that required a personal licence.)
Definition of key terms:
In vivo skills are broadly defined as including any 
skills that are required to conduct research that uses 
live animals and is regulated under the auspices of 
the Animals (Scientific Procedures) Act 1986 (the 
A(SP)A, and subsequent revisions). The definition 
is not restricted, however, to only the activities 
specified in the legislation. In vivo skills also include 
the competence to perform particular procedures, 
such as stereotaxic surgery or the administration of 
anaesthesia, the ability to handle animals, to ensure 
that they are cared for in a species-appropriate way, 
to have relevant knowledge of the physiology and 
behaviour of relevant species, and to be able to 
design, conduct and analyse experiments to ensure 
that animal welfare is considered and high quality 
data are produced. 
In vivo education is defined as any intervention that 
occurs within the taught curriculum, with the content 
primarily designed by academic staff. 
In vivo training is defined as any hands-on experience 
undertaken as part of Home Office modular training 
courses or the acquisition of vocational/technical 
skills during a programme of research. This includes 
‘on the job’ training as part of participation in research 
conducted under a supervisor’s project licence. 
92. THE INTEGRATIVE 
PHARMACOLOGY FUND
2.1. BACKGROUND AND AIMS 
The IPF was intended to address the need for in vivo training identified 
by the ABPI and Biosciences Federation reports and was supported by 
contributions totalling £4 million from AstraZeneca, GlaxoSmithKline 
(GSK) and Pfizer. 
The aim of the IPF was to develop strategies to support 
in vivo research and training in Pharmacology, Physiology 
and Toxicology in the UK. It was led by a steering group 
comprising representatives of the funders: Dr Martin 
Todd (AstraZeneca); Dr Malcolm Skingle (GSK); Dr 
Mike Collis (Pfizer); and Professor Sue Brain (British 
Pharmacological Society). 
A strategic decision was made by the steering group that 
the IPF would work with national funding bodies (the 
Biotechnology and Biological Sciences Research Council, 
BBSRC; the Medical Research Council, MRC; and the 
Higher Education Funding Council for England, HEFCE) to 
support in vivo education and training. This collaborative 
approach resulted in the £4 million contributed to the 
IPF leveraging total support of £22 million for in vivo 
research, education and training.
The IPF sought to sustain the complete academic pipeline 
of in vivo training and development – from undergraduate 
to Master’s, PhD, fellow and lecturer – through the 
funding of Master’s courses, PhD studentships, 
academic fellowships, project (pump-priming) grants 
and permanent lectureship positions. The rationale for 
this approach was that funding only one phase of the 
development of the next generation of in vivo scientists 
would not succeed in rebuilding the expertise base, 
as the phases are mutually dependent. The British 
Pharmacological Society and The Physiological Society 
already supported undergraduate in vivo education 
and the IPF offered financial support to these existing 
schemes (see Figure 1 and Table 2).
Initial offers of funding from the IPF were made 
jointly with Research Councils UK (RCUK; for Academic 
Fellowships) and the BBSRC and MRC (for targeted in 
vivo PhD studentships, Master’s courses and industrial 
partnership grants). The IPF grants were distributed to 20 
different academic institutions in the UK.
The high cost of the facilities and infrastructure required 
for animal research and training led the steering group 
to favour a targeted approach, rather than providing 
small awards to a large number of academic institutions. 
A strategy was therefore developed to establish a small 
number of Centres of Excellence.
Discussions were initiated with the BBSRC, MRC, HEFCE, 
the Scottish Funding Council (SFC) and the Department of 
Trade and Industry (DTI) to establish a funding partnership 
to provide five-year grants of £3 million for up to four 
centres of in vivo excellence (Integrative Mammalian 
Biology Capacity Building Centres, or IMB centres). The 
centres were selected for their world-class expertise in in 
vivo integrative pharmacology, physiology and toxicology, 
high-quality infrastructure, well-defined strategy for in 
vivo research and their long-term commitment to support 
animal welfare and public outreach. 
Aims of the IMB Centre awards: 
  Provide ‘springboard’ funding to enhance high quality research and training in integrative mammalian biology
  Provide ‘seed-corn’ funding to enhance the higher education institution’s strategy in integrative 
mammalian biology
  Foster an environment that attracts and supports the required diversity of top-quality scientists, who 
conduct research at the highest level, and train and develop the next generation of researchers in good 
practices in integrative mammalian biology
  Equip the next generation of researchers with the expertise and skills in understanding the ethics 
surrounding the use of animals in research, high quality experimental design and the application of a 
broad range of techniques and approaches in integrative mammalian biology
  Promote awareness of the importance of this area of science
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Figure 1 – Timeline of drivers of the IPF and changes in animal research (turquoise boxes above the timeline) and elements of the IPF intervention (blue boxes below 
the timeline). 2004 marks the start of the IPF initiative. Acronyms: BBSRC – Biotechnology and Biosciences Research Council, MRC – Medical Research Council.  
Image credit: Dave Lewis
IMB centre awards were made to Imperial College 
London and King’s College London individually and to two 
consortia of universities: the Universities of Manchester 
and Liverpool, and the Universities of Glasgow and 
Strathclyde. Within the guidelines of building capacity 
and sustainability of high quality research, education and 
training, institutions were given flexibility to propose how 
they would use the IMB centre awards. The recipients all 
provided (and in most cases established) Master’s courses 
and/or new undergraduate modules, funded a number 
of in vivo PhD studentships, recruited postdoctoral staff 
as lecturers to build teaching capacity, and established 
management boards. The University of Manchester IMB 
centre appointed an Experimental Officer to provide 
expertise in in vivo studies.
The IMB centres reported on their activities to the 
steering committee each year. The IPF-supported 
members of staff had to report on their in vivo education, 
training, research and outreach activities. In addition to 
this more formal monitoring, there was informal tracking 
of the progress of the centres and individuals by members 
of the steering committee.
The remaining money left in the IPF after these major 
grants had been awarded was used for pump-priming 
grants, aimed to enable in vivo scientists to conduct the 
preliminary studies necessary to develop major project 
grant applications. With the end of the IPF funding, 
evaluation of the use of its funds and the outcomes 
generated is required to guide activity and support post-
IPF. This also requires consideration of how the general 
landscape of in vivo research has changed in the UK since 
the IPF was launched in 2004. 
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2.2. CURRENT LANDSCAPE
In vivo techniques are used primarily in universities, medical schools 
and commercial organisations. According to Home Office statistics 
on the number of scientific procedures conducted in 2015 under 
the auspices of the amended A(SP)A, 48% of the total 4.14 million 
procedures (a small increase since 2014) are conducted in universities 
and medical schools, 25% in commercial organisations, with the rest of 
the procedures primarily conducted in other public bodies and non-
profit organisations.3 
Figure 2 shows the number of licensed procedures in the 
university-medical school sector and the commercial 
sector over the last decade, showing an increase in 
procedures in academic institutions, and the initial 
increase in the commercial sector up to 2008, which 
declined and levelled over the following years. 
Half of the procedures in 2015 involved the creation 
or breeding of genetically-altered animals not used in 
further procedures. Continued small increases overall, 
and a somewhat larger increase over the last decade in 
the number of procedures in academic research, indicates 
a continuing need to ensure the highest possible quality 
science and animal care for all recorded procedures on 
animals. 
Figure 2 – The number of licensed procedures in universities and medical 
schools and the commercial sector, from 2006 to 2015 inclusive. From 2013, 
new reporting systems have been used. Source: Home Office3 
Since the start of the IPF, there have been significant 
shifts in the landscape of in vivo research in the UK. The 
regulatory framework has changed with the transposition 
of EU Directive 2010/63/EU into UK law. Institutions 
that have establishment licences must appoint named 
individuals to take responsibility for ensuring: that people 
working with animals are properly educated, trained and 
competent (the Named Training and Competency Officer, 
3 Home Office (2016) Annual Statistics of Scientific Procedures on 
Living Animals Great Britain 2015. Available online at: https://www.gov.
uk/government/statistics/statistics-of-scientific-procedures-on-living-
animals-great-britain-2015
NTCO); that they have access to relevant information 
concerning their work with animals (the Named 
Information Officer, NIO); that standards of welfare and 
care of animals are upheld (the Named Animal Care and 
Welfare Officer, NACWO), and that the requirements of 
the A(SP)A and licence conditions are upheld (the Named 
Compliance Officer, NCO). Additionally, at least one 
Named Veterinary Surgeon (NVS) should be appointed 
to advise on the health and welfare of the animals. 
Further, in addition to the initial provision of education 
and training, there is now a legal requirement to assess 
and ensure the technical competency of personal licence 
holders throughout their career and for both personal 
and project licence holders to engage in Continuing 
Professional Development.
There has also been a renewed focus on advancing the 3Rs, 
and the creation of the National Centre for the 3Rs (NC3Rs) 
has been a catalyst for new work (by funding PhD projects, 
for example), collecting and disseminating good practice, 
and developing tools such as the Experimental Design 
Assistant (EDA). The EDA in part is intended to address 
perceived problems with the quality of results produced in 
areas of biomedical research. The concerns have focused 
on the design and conduct of experiments, and the 
analysis and interpretation of data generated in them.
There has been a period of considerable change in higher 
education in the UK, with the introduction of student 
fees, and strategic review for funding councils, with a 
general emphasis on demand management and the co-
ordination of research around grand challenges. Support 
for in vivo research has been through initiatives such as 
the Strategic Skills Awards, and amendments to Doctoral 
Training Partnerships to allow for additional funds for 
more expensive in vivo research for students. 
In higher education more broadly, the introduction of 
the impact agenda through the Research Excellence 
Framework (REF) encourages researchers to demonstrate 
the impact of their research. Impact is considered 
“an effect on, change or benefit to the economy, 
society, culture, public policy or services, health, the 
environment or quality of life, beyond academia”.4 
4 Research Excellence Framework (2012) Assessment 
framework and guidance on submissions. Available 
online at: http://www.ref.ac.uk/media/ref/content/pub/
assessmentframeworkandguidanceonsubmissions/GOS%20including%20
addendum.pdf
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As well as potentially incentivising translational 
research, impact can also include affecting or changing 
“the activity, attitude, awareness, behaviour, capacity, 
opportunity, performance, policy, practice, process or 
understanding… an audience, beneficiary, community, 
constituency, organisation or individuals”.5 This can 
therefore include outreach and public engagement, as 
well as contributing to policy development. 
The growing movement towards a more open science has 
also influenced the in vivo research landscape. Concerns 
about the reproducibility of data produced in biomedical 
research have led to the development of new guidelines 
on the publication of methods and data.6 Separately, a 
new approach to increasing transparency and facilitating 
public engagement was pioneered by Understanding 
Animal Research and members of the UK biosciences 
community through the 2012 Declaration of Openness on 
Animal Research. The launch of the subsequent Concordat 
on Openness on Animal Research7 in 2014 has encouraged 
organisations and individuals to commit to be more open 
about the use of animals in their research, and to engage 
constructively with members of the public.8 Alternative 
metrics to include public engagement activity may need 
to be developed to encourage this in addition to the 
impact case studies, see Recommendation 10.
The industry landscape has changed, with a decline in 
the research base of large pharmaceutical companies 
and growth in small to medium sized enterprises (SMEs) 
in the UK.9 According to the latest set of figures from the 
Office for National Statistics, research and development 
spending in the pharmaceutical industry declined in real 
terms in successive years from 2011 to 2014, at a time 
when overall UK research and development spending 
increased according to the same measure.10 Smaller 
biotechnology companies and Contract Research 
Organisations (CROs) are now increasingly important for 
conducting or sponsoring in vivo studies in the UK. 
5 Research Excellence Framework (2012) Assessment framework and 
guidance on submissions. Available online at:  
http://www.ref.ac.uk/media/ref/content/pub/
assessmentframeworkandguidanceonsubmissions/GOS%20including%20
addendum.pdf 
6 Institute for Laboratory Animal Research (2015) Reproducibility Issues 
in Research with Animals and Animal Models. Available online at:  
http://www.nap.edu/catalog/21835/reproducibility-issues-in-research-
with-animals-and-animal-models-workshop
7 Understanding Animal Research (2016) The Concordat on 
Openness on Animal Research. Available online at: http://www.
understandinganimalresearch.org.uk/policy/concordat-openness-animal-
research/
8  Leonelli S et al (2015) Sticks and carrots: encouraging open science at 
its source, Geo: Geography and Environment, Vol. 2: 12-16. 
9 ABPI (2016) The Changing UK Drug Discovery Landscape. Prepared by 
TBR’s Economic Research Team and CBSL. Available online at:  
http://www.abpi.org.uk/our-work/library/industry/Documents/the-
changing-UK-drug-discovery-landscape.pdf
10 See: Office for National Statistics (2015) Business Enterprise Research 
and Development: 2014. Available online (with accompanying data) at: 
https://www.ons.gov.uk/economy/governmentpublicsectorandtaxes/
researchanddevelopmentexpenditure/bulletins/
businessenterpriseresearchanddevelopment/2014
There is also additional sub-contracting of projects and 
tasks by large pharmaceutical companies to university-
based laboratories, in part through the development of 
partnerships and collaborations such as GSK’s ‘Discovery 
Partnerships with Academia’, Pfizer’s ‘Centers for 
Therapeutic Innovation’ and AstraZeneca’s research 
partnerships.11 
The closure of some of the larger pharmaceutical 
company research facilities means that there is, 
temporarily at least, a large number of scientists with in 
vivo skills available, but this may not always be the case. 
Training within the large pharmaceutical companies 
has also changed. Whereas previously large companies 
would employ school-leavers who could then complete a 
BSc and perhaps a PhD while in post, this is no longer the 
case. The introduction of degree apprenticeships in 2015, 
in addition to the existing model of apprenticeships, 
may provide an alternative pathway for individuals to 
receive ongoing in vivo skills education and training, 
as well as career progression. It may also be a space for 
the development of new forms of cooperation between 
academia and industry. 
In addition, the referendum vote for the UK to leave 
the European Union is expected to impact upon the 
pharmaceutical sector and research more broadly.12 The 
possible implications of this include barriers to obtaining 
grants and collaborating with colleagues in Europe, but 
also potential staffing problems, with a high proportion 
of laboratory staff in some institutions coming from 
non-UK EU countries. The UK research and development 
landscape is therefore characterised by uncertainty, and 
the task of those concerned with the future of in vivo skills 
and research is to ensure that there is sufficient flexibility 
and resilience to ensure that short-term changes and 
events are managed or capitalised upon.
Organisations such as the British Pharmacological 
Society, other learned societies and Research Councils 
have a responsibility to safeguard the future of in vivo 
research, in the context of wider challenges in the 
political, economic, industrial or academic landscapes. 
11 Information on these partnerships are available at:  
www.dpac.gsk.com  
www.pfizer.com/research/rd_partnering/centers_for_therapeutic_innovation 
www.astrazeneca.com/partnering/partnering-case-studies.html
12 British Pharmacological Society (2016) The European Union 
Referendum. Available online at: https://www.bps.ac.uk/about/the-
european-union-referendum.
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3. METHODS AND EVALUATIVE 
CRITERIA
3.1. METHODS
The evaluation was based on a mixed methodology. We collected 
and analysed quantitative and qualitative data to inform the 
evaluation of the immediate outcomes and longer-term impacts of 
the IPF investments. The evaluation team worked collaboratively 
with the IPF participants and wider stakeholders to add further data 
and interpretation at a workshop based on the interim draft of the 
evaluation report. 
The sources, samples and contribution of the data collected for the evaluation are summarised below, and described 
further in the remainder of this section. 
Source Sample Data/Contribution
Questionnairea (online) Link to online questionnaire sent by email 
to Master’s/PhD students who received 
the IPF support and fellows/staff 
appointed with the IPF support.
Quantitative and qualitative data for 
evaluation. Informed development 
of methodology for selection of 
interviewees and content of interviews.
Grant Questionnaireb 
(emailed)
Sent by email to recipients of pump-
priming grants funded by the IPF.
Qualitative data for evaluation. Informed 
development of methodology for 
selection of interviewees and content of 
interviews.
Education Surveys 
(administered by 
institutions)
Undergraduate students who took 
education modules or short courses 
supported by the IPF
Mainly quantitative data analysis (but 
also some qualitative analysis) for 
evaluation and to inform potential 
recommendations.
Interviews (interviewed by 
James Lowe)
Master’s/PhD students who received the 
IPF support, fellows/staff appointed with 
the IPF support, senior figures at IMB 
centres. 
Recorded, transcribed and coded data 
used to analyse and evaluate the various 
facets of the IPF and pick up on potential 
areas of recommendation. 
Roundtable Meeting 
(facilitated by the British 
Pharmacological Society)
Senior figures at IMB centres. Data from recordings and notes used 
to assess and evaluate the work of 
the IMB centres, their legacy and the 
sustainability of in vivo education, 
training and research in those 
institutions.
Stakeholder Workshop 
(facilitated by the British 
Pharmacological Society)
Stakeholders from academia, industry, 
learned societies, animal welfare 
organisations, industry bodies, research 
councils.
Data from recordings and notes used to 
assess and provide further evidence for 
the evaluation. 
Follow-up Interviews 
(interviewed by James Lowe)
Non-IPF supported researcher, industry 
figures, in vivo educators.
Data from recordings and notes 
used to assess and further shape 
recommendations.
a See appendix 3, available online at www.bps.ac.uk/futureinvivo
b See appendix 4, available online at www.bps.ac.uk/futureinvivo
Table 1. Overview of research methods
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In December 2015, the team circulated a questionnaire 
by email to two groups of recipients of support from 
the IPF: Master’s/PhD students and fellows/staff. The 
questionnaire gathered quantitative and qualitative 
data concerning the effect of the IPF support on their 
careers and their views of the future prospects of in vivo 
research. For the Master’s/PhD group, 70 individuals with 
active contact details were identified and contacted by 
email, of whom 32 responded (46%), and 25 completed 
the questionnaire (38%). For the fellows/staff group, 21 
were contacted, of whom 17 responded (81%), 16 of these 
fully completed the questionnaire (76%), and 1 partially 
completed it. The response rates, aided perhaps by 
personalised emails to potential respondents, was high 
for an online survey. 
In addition to this questionnaire (see appendix 3 online), 
a separate questionnaire was distributed to 6 recipients of 
pump-priming grants (see appendix 4 online), the team 
also reviewed exit feedback from undergraduate modules 
and short courses supported by the IPF, and analysed a 
more substantive survey of students who took the Level 6 
undergraduate education module ‘Integrative Biomedical 
Science’ at the University of Leeds from 2005 to 2015.
Data from a questionnaire circulated in December 2015 
was used to identify potential follow-up interviewees, 
sampling for different exposures to the initiative (i.e., 
position and type of support, presence at an IMB centre 
or non-IMB centre), involvement in education and 
training (including being able to offer insights about the 
education and training they have received), and the status 
and progress of an individual’s research career. In-depth 
interviews were carried out with 20 people supported by 
the IPF in a variety of capacities, including: undergraduate 
attendee at a short residential course, Master’s student, 
PhD student, appointed Fellow, appointed Lecturer, 
appointed Experimental Officer, and existing staff 
member at one of the IMB centres established through 
the initiative. The interviewees also encompassed 
different areas of work: neuroscience, immunology and 
cardiovascular research, as well as research support. 
Furthermore, there were interviewees who are no longer 
involved in academic research or training. 
The interviews were 
conducted by James Lowe, 
as an evaluator external to 
the British Pharmacological 
Society. Interviewees were 
offered a choice of different 
levels of confidentiality, 
including complete 
anonymity, disclosure of 
role and/or organisation 
and full disclosure. The 
interviews were recorded and transcribed, and the 
qualitative research software package NVivo was used to 
code the transcripts using evaluative criteria developed 
over several iterations of initial analysis. 
Subsequent to the interviews, a roundtable meeting was 
organised at which senior members of staff associated 
with IMB centres were present, and were able to share 
their reflections on the initiative, its legacy, and future 
challenges and opportunities for in vivo research. 
In May 2016, a workshop was held with invited 
stakeholders from research councils, industry and 
industry bodies, academia, and learned societies. This 
stakeholder workshop included presentations from 
selected participants and discussions on the data 
collected so far. The discussions and proposals emanating 
from this workshop were fed into the evaluation, and 
also informed a set of recommendations which were then 
developed and made more specific. Further interviews 
and conversations followed the stakeholder workshop in 
order to finalise the evaluation and recommendations. 
3.2. EVALUATIVE CRITERIA
The outcomes of the IPF were assessed against four 
evaluative criteria, each of which can be exemplified 
through a question, as follows: 
To what extent has the IPF contributed to improving 
community capacity for in vivo education, training 
and research? 
This includes evaluation of the overall contribution 
of the IPF to addressing the identified skills gaps, 
enhancing capacities for providing education and 
training, strengthening the quality and effectiveness 
of training, and developing a legacy and sustainable 
future for in vivo education, training and research. By 
legacy we mean the structures, skills and research 
culture which endure in institutions beyond the 
cessation of the IPF support.
To what extent has the IPF contributed to individual 
career development? 
This includes evaluation of the contributions of the 
IPF training, funding and positions to individual 
career advancement, the development of group 
and grant activities, and the direct and indirect 
contribution of in vivo skills education and training to 
both careers and the wider scientific community.
To what extent has the IPF contributed 
enhancements to research practice and outcomes? 
This includes evaluation of the contributions of the 
IPF education, training, funding and positions to 
changes in research practice, including experimental 
design, potential for translational research, and 
advancements in terms of the 3Rs (especially 
improving practices through reduction and/or 
refinements).
To what extent has the IPF contributed to the 
development of research networks, dissemination 
and collaboration? 
This includes evaluation of the contribution of the 
IPF investments in networks, hubs and outreach 
activities to the development of collaborative links 
and research projects, the sharing of current good 
practices in research and the 3Rs, dissemination of 
results and public engagement with research.
Qualitative interviews 
produced:
1,406 minutes of 
interview recordings
328 pages of transcripts
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These criteria were developed by considering three main 
groups of drivers: 
1.  The original aims expressed for the IPF and 
subsequent IMB centre awards; 
2.  The interpretation and development of aims by 
participants involved in the activities of the IPF and 
IMB centres; 
3.  Emerging issues for the future of in vivo education, 
training and research that were identified by 
participants during interviews and at the roundtable 
discussion.
Discussions of all three provide valuable information 
for this assessment. Because the IPF was not narrowly 
prescriptive in what it demanded from bids for IMB centres 
or for other support such as funds for fellowships and 
studentships (beyond the requirement for high standards 
of research, education, training, animal welfare and 
outreach), many additional aims were generated by those 
in receipt of support from the IPF, whether institutions or 
individuals. This report seeks to capture these. 
In addition, the evaluation criteria reflect a range of 
issues that have emerged since the inception of the 
project and are now important for any consideration 
of the future in vivo education, training and research. 
As indicated above, these include, but are not limited 
to: the decline in the R&D base of large pharmaceutical 
companies in the UK; the advent of the Concordat on 
Openness which has changed the way researchers and 
institutions approach communications and public 
engagement; the development of the work of the NC3Rs, 
with an increased focus on animal welfare and the 3Rs; 
legislative changes as a consequence of the transposition 
of the EU Directive 2010/63/EU into UK law; and changes 
to doctoral training schemes, including the creation of 
Doctoral Training Partnerships (DTPs). 
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4. THE INTEGRATIVE 
PHARMACOLOGY FUND OUTCOMES
4.1. COMMUNITY CAPACITY 
Interviewee perspectives on meeting community capacity: 
“It raised the profile of in vivo biology and to some extent has offset that tendency to lose those skill sets.” 
(Interviewee FS7, IMB centre)c
“Without the framework to hold onto the people, you’re just going to lose them long-term.” 
(Interviewee MP5, IMB centre)
These two quotes encapsulate the overarching theme of this section. The IPF trained large numbers of people in a range 
of in vivo research skills. The concerns expressed by those who were supported by the IPF or who worked at IMB centres 
relates to the long-term retention of those skills, and therefore the sustainability of the results of the IPF intervention.
Establishing the IPF and building community capacity
The IPF successfully brought together multiple stakeholders to leverage the initial £4 million into a sum of £22 million, 
and to fund eight Academic Fellowships, 102 PhD studentships, 106 Master’s students, five in vivo short courses, 
between six and eleven undergraduate modules (the figure varied over time), and twelve pump-priming grants. Four 
centres of excellence were established across six universities (Table 2). 
Level Number supported Funding partner 
Pump-priming grants 12 None
Lectureships 12 IMB centre funders
Academic fellows 8 RCUK 
PhDs 102 BBSRC/MRC
CRUK 
IMB centre funders
Master’s students 106 BBSRC/MRC
IMB centre funders
Short residential courses 5 British Pharmacological Society/ 
The Physiological Society 
BBSRC
MRC
Wellcome 
IMB centre funders
Undergraduate courses 6–11 Pharmaceutical companies, CROs, Resource 
Suppliers, British Pharmacological Society
Table 2 – The number of people/courses supported by the IPF and funding partners.
c Codes have been used for interviewees to preserve anonymity while still signalling their role. FS is someone who was appointed as a fellow or staff with 
IPF support or otherwise in that position and at an IMB centre, MP denotes someone who was an IPF-supported postgraduate student.
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The IMB centre of excellence model supported by the IPF 
leveraged the initial funds provided by the IMB centre 
funding consortium producing outcomes that were, in 
quantitative terms, in excess of the initial expectations, 
as the figure below indicates. This increased productivity 
was due to the success of the IMB centres in gaining 
additional non-IMB centre funding to support additional 
students and staff (including a Business Development 
Manager at Manchester/Liverpool and an Industrial 
Impact Fellow at King’s College London). The IMB centres 
acted as “honey pots” for additional grant funding, 
illustrating the advantages of establishing virtual centres 
of excellence for in vivo research and training. 
Figure 3 – Graph depicting numbers of people originally envisaged to be 
supported by the IMB centres, and those actually supported through 
additional non-IMB centre grants.
The focus of the IPF was on the provision of courses and 
training at research-intensive universities. One of the key 
aims was to replace lecturers nearing retirement. The 
original loss of academic teaching staff was projected 
to be 56. This figure comes from the assessment by the 
British Pharmacological Society and The Physiological 
Society in 2004 of those projected to retire within the 
following five years. There is evidence that not all who 
have formally retired have ceased teaching, for example 
at The University of Manchester and King’s College 
London. Through the appointment of new lecturers, 
and of fellows with a gradually increasing teaching load 
who would become lecturers after five years (pending 
satisfactory performance), undergraduate education 
capacity has been preserved. Based on the results of the 
questionnaire, 21 new academic staff were appointed as a 
result of the IPF, of whom at least 15 are still involved in in 
vivo education and training in the UK. Based on interview 
responses, staffing levels do not currently appear to 
be a limiting factor for undergraduate or postgraduate 
in vivo education and training. Rather, it is the cost of 
this education and training that limits provision. Of 
the courses supported by the IPF, the Master’s at the 
Imperial College London IMB centre has ceased, and 
the standalone Master’s degree at the University of 
Manchester has ended. Lack of funds to run courses were 
cited as the reason for both of these closures. 
Additional funds from the research councils are not 
likely to be forthcoming, but the Strategic Skills Awards 
were valued by researchers. The Strategic Skills Awards 
(funded by the MRC and BBSRC) provided additional funds 
to support the running costs of in vivo PhD studentships. 
The Awards were originally made for individual projects 
following review by the IPF steering committee and the 
NC3Rs. Additional top-up funding for in vivo research is 
now incorporated into DTP funding.
Taught courses and PhD studentships
New undergraduate and Master’s courses were developed, 
and old courses continued. Eleven of the new staff 
appointed have been involved in the setting up of new 
courses. 640 undergraduates received in vivo training at 
the IMB centres. One lecturer commented in an interview 
that, “the number of undergraduates and Master’s 
students that I trained was as a consequence of British 
Pharmacological Society involvement. I would have done 
far fewer if people weren’t expecting me to do in vivo.” 
One new course, at King’s College London, was pioneered by 
two IPF-supported fellows. The way in which they approached 
teaching statistics to biology and biomedical sciences 
undergraduates has led to a new online method for teaching 
statistics to the whole school (up to 1,200 students). 
Although those employed on permanent contracts will 
remain after the cessation of the IPF and related funds, 
and therefore constitute an ongoing legacy in terms of 
teaching capacity, the sustainability of some of these 
courses, or at least the training of in vivo practical skills in 
them, was thought to be in doubt at some institutions. A 
variety of funding issues contribute to this uncertainty, 
including debate over the relative cost and value of 
personal licences for students’ in vivo education. 
The IPF fellows and lecturers have contributed 
significantly to Master’s training, which was a key part 
of the education and training operations of the IMB 
centres. The IPF directly funded PhD studentships, and 
the IPF fellows and staff were able to successfully obtain 
grants or leverage their positions in other ways to obtain 
additional PhD studentships and top-up funds. 
Skills gap and ongoing skills concerns
A review of ‘vulnerable skills’ conducted by the BBSRC and 
the MRC in the summer of 2014 highlighted continuing 
concerns about the training, career pathways, recruitment 
and future supply of people with in vivo research skills. In 
its November 2015 report entitled ‘Bridging the skills gap 
in the biopharmaceutical industry,’ the ABPI downgraded 
in vivo sciences as no longer being an area of ‘high priority’ 
concern, but “although concerns over in vivo pharmacology 
and animal technology have reduced slightly, they are 
still medium priorities”.13 A caveat here is that the ABPI 
considered in vivo pharmacology to consist of safety 
pharmacology, and areas that might be considered to be 
pharmacology were included under in vivo physiology, 
which was deemed to be an area of major concern. This 
in itself is evidence of the different definitions used by 
industry and by academic researchers, and points to a 
need for improved dialogue between the sectors.
13 ABPI (2015) Bridging the skills gap in the biopharmaceutical industry. 
Available online at: http://www.abpi.org.uk/our-work/library/industry/
Documents/Skills_Gap_Industry.pdf
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The same report concluded that interventions such as 
the IPF and the IMB centres “have been effective and 
it is essential that, as funding for some such initiatives 
approaches its end, activity in these areas continues to 
avoid recurrence of skills gaps in these areas”. It is a strong 
possibility, however, that the reduction in in-house 
research capacity in large pharmaceutical companies in 
the UK has resulted in significant numbers of scientists 
with in vivo skills entering the labour market, thus 
reducing the pharmaceutical industry’s concerns about 
supply. In contrast to industry, demand for in vivo 
scientists in academia is increasing. Thus, any perceived 
increased availability of people with in vivo training and 
skills may only be temporary.
The concerns about sustainability raised in both reports 
were shared by interview respondents. The expense of in 
vivo training and research means that there are concerns 
that these gains may be lost without specific and targeted 
funding that supports the improvements in teaching and 
research capacity. 
In particular, concerns were raised that without 
guaranteed top-up funds, Principal Investigators (PIs) 
are not putting forward PhD studentships. Without 
a guarantee of extra funding on top of a stipend and 
small additional budget, a PhD student may not be 
able to conduct in vivo research, or may only do so at 
considerable cost to the laboratory. Since many in vivo 
research groups are small, and may not have the money 
to absorb these costs, there is a disincentive to put 
forward in vivo PhD studentships. 
The Doctoral Training Partnerships (DTPs) grants, 
available to universities from RCUK, have been criticised 
for not taking account of the elevated costs of in vivo 
training and research. Subsequently, the scheme has 
been modified to allow for DTPs to apply for top-up 
funding for more expensive in vivo research. At the 
stakeholder workshop, representatives from the BBSRC 
and MRC explained that they sought the “best return” on 
their investment in research, which could mean funding 
more expensive projects with better outcomes and 
impact than less expensive projects. 
Other stakeholder workshop participants noted the 
importance of other ways of training for in vivo skills. 
These include being trained by industry, for example 
through the hiring of 
graduates and apprentices. 
Degree apprenticeships, 
in which apprentices work 
in a relevant company 
while also studying for a 
degree-level qualification, 
offer a potential route 
towards the development 
of in vivo skills that may 
not require additional 
funding of courses or staff 
at universities. 
In bids from institutions 
to host IMB centres, the 
IPF explicitly required 
guarantees of institutional 
support for in vivo work and the aims of the initiative. 
In particular, they sought evidence of higher-level 
institutional support. At the stakeholder workshop, this 
higher-level support from senior colleagues, as well as 
the continued involvement of senior IMB centre staff, 
was emphasised as an important factor in ensuring 
that certain parts of the initiative continue to run, such 
as undergraduate courses or in vivo Master’s courses. 
During roundtable discussions, there was concern about 
the legacy of the IMB centres, and this was strongly 
associated with the sustainability of the initiatives 
established at the IMB centres. Permanent members of 
staff were cited as the only ongoing legacy beyond this 
year by a senior member of one IMB centre, and in that 
sense specific individuals embody the legacy. At other 
IMB centres, courses remain and some of the institutional 
architecture and networks put into place during the 
period of the IMB centre persist.
Research grants
Having been appointed, 
fellows and lecturers 
have been able to use the 
limited funds allotted to 
them as part of the IPF 
scheme and the work of 
the IPF-supported PhD 
students (and, to a lesser 
extent, Master’s students 
on rotation in their 
laboratory) to leverage 
further grant funding, for 
instance by producing pilot data that was then used in 
grant applications. Although some have found obtaining 
grant funding difficult, a majority has been able to 
obtain grants to fund several generations of PhDs and 
postdoctoral researchers through their laboratory. 
Technical skills, technicians and 
technologists
There is considerable concern about non-research skills 
capacity; in particular, that funding is insufficient to 
appoint and retain animal technologists and/or research 
technicians. Researchers noted several benefits of having 
technicians or animal technologists, namely performing 
procedures and allowing research to continue in the 
absence of the PI, undergraduate education, training of 
researchers and postgraduates, and providing stability 
and continuity of skills, amidst losing skills acquired 
by PhDs and postdoctoral researchers when they move 
on. The responses of multiple interviewees concurred 
with the view that, while individual researchers value 
technicians and technologists, institutions tend not to. 
Many of the researchers and other stakeholders pointed 
out that, when institutions (be they academic or 
industrial) have technicians or animal technologists 
trained in procedures such as blood pressure monitoring 
and telemetry, there is a considerable impact in terms 
of research productivity. They are able to optimise and 
standardise procedures, and also have closer access 
to some knowledge-networks concerning welfare and 
experimental practices that researchers may not. 
RECOMMENDATION
Establish apprenticeships 
for in vivo sciences
Higher education 
institutions, the British 
Pharmacological Society, 
the ABPI, and industrial 
and clinical partners 
should collaborate 
in the development 
of pharmacology 
apprenticeships, 
including degree 
apprenticeships.
Grant success for the 17 
fellows and staff:
15 (88%) held non-IPF 
grants. Of these, 14 
(93%) believe that their 
prior IPF-supported work 
enabled them to win 
these grants.
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The role of the 
Experimental Officer 
appointed to the IMB 
centre at The University 
of Manchester is an 
instructive example of 
how someone appointed 
to a non-research role – in 
this case a postdoctoral 
position – can enhance 
the research and training 
capacity of a university. 
This individual has become 
a repository of in vivo skills 
and current good practice; 
delivers Home Office 
training not just at the 
University of Manchester 
but more widely as well; 
is involved in ensuring 
that current good practice 
is disseminated to the 
appropriate people, 
and coordinates animal research. The role of the 
Experimental Officer has evolved since its inception, and 
is now underwritten by the University as a University-
wide role. The Experimental Officer serves as the Named 
Information Officer (NIO) and the Named Training and 
Competency Officer (NTCO) under the auspices of A(SP)
A. The role works because of the institutional support for 
the position (including, but not restricted to, the salary), 
the holder’s experience and training in conducting in vivo 
techniques, clear lines of management, and the fact that 
being appointed to a University-wide role helps to break 
down the academic silos inhibiting joint-work between 
different faculties. 
In industry, there is less of a fundamental divide 
between laboratory animal technologists and scientists, 
with technologists in some companies encouraged to 
contribute towards the design of experiments, as well 
as conducting procedures and analysing data. Career 
progression and development is in some cases geared not 
towards the academic background of the individual or 
the job on entry, but to the aptitude and interests of the 
individual. In some companies, the title of ‘technician’ 
or ‘technologist’ has been dispensed with altogether, 
with people traditionally regarded as such being treated 
instead as research support. Discussion at the stakeholder 
workshop indicated that the organisation of academic 
research around specific costed projects can make this 
kind of ongoing core support difficult to fund within 
higher education institutions. 
Student progression and retention
Interviewees who were on the Master’s at Imperial 
College London cite many colleagues who are no longer 
in research, but attribute this to the natural attrition in 
academic research. A commenter at the University of 
Glasgow believed that many who had gone through the 
Master’s and the PhD were no longer using their in vivo 
training. The picture at the University of Manchester is 
different, with high levels of progression from Master’s 
to PhD, and even from PhD to postdoctoral researcher 
reported. A member of staff at Imperial College London 
reported a higher progression to postdoctoral researcher 
positions from the IPF-funded PhD students. There may 
not be a contradiction between these experiences, as the 
conversion from PhD to 
postdoctoral researcher 
(and beyond) is notoriously 
low in general.14,15 The 
higher progression rates 
could be explained by the 
advantages possessed by 
students who took Master’s 
courses, which provided 
them with a personal 
licence and research 
training and experience, 
as well as matching them 
up with potential PhD 
supervisors. As one former 
postgraduate at an IMB 
centre put it: “Different 
labs have got different 
feels, it can be very difficult 
to get a feel for that until 
you’re actually in it.” 
Of the 25 respondents to 
the questionnaire who had 
taken Master’s degrees 
and/or PhDs with the IPF 
support, 23 (92%) are in 
science-based careers or 
training, and 14 (56%) use 
in vivo skills in their current 
role. Those that do not 
use in vivo skills practically 
cite their training as useful 
in providing a better 
appreciation of data and 
assessing the practical in 
vivo work of others. 12 of 
the 25 (48%) train others 
in in vivo skills. 
4.2. CAREER DEVELOPMENT
A key part of the IPF’s aim of increasing in vivo skills 
capacity was ensuring that sustainable and successful 
careers and career pathways were secured for those 
trained in in vivo research. An important part of this 
evaluation therefore concerns the career development 
of individuals. The main focus will be on fellows, staff 
and postgraduates, as this was the main focus of the 
IPF intervention. Fellows and staff supervise and secure 
funding for PhD students, and in turn Master’s and PhD 
students contribute to the research of the PI’s group as a 
whole. 
In the section on Master’s and PhD students, attention 
14  Cyranoski D et al (2011) Education: The PhD Factory, Nature, Vol. 472: 
276-279.
15  Powell K (2015) The future of the postdoc, Nature, Vol. 520 No. 7546: 
144-147.
RECOMMENDATION
Support integrated 
pathways for technicians 
and animal technologists
There should be strong 
institutional support 
for career progression, 
skills training and job 
security for technicians 
and animal technologists. 
Laboratory animal 
technologists should be 
more integrated into the 
planning and conduct of 
academic research and 
preclinical research and 
development, both in 
industry and academic 
research. 
Evidence of student 
progression (2012 data 
IMB Centres):
58 of 67 Master’s Students 
(87%) had gone on to a PhD. 
17 of 25 PhD students 
(68%) now held 
postdoctoral positions. 
3 (12%) had jobs in the 
pharmaceutical industry. 
Further study for taught 
Master’s students 
for 2011/12: 27% for 
biomedical sciences 
and 21% for biological 
sciences.* 2009 study 
of 2007 biology PhD 
awardees, 61% in 
university and other 
research.**
*Universities UK (2014) 
Taught Postgraduate 
Employability and Employer 
Engagement: Masters with a 
purpose. Available online at: 
http://www.universitiesuk.
ac.uk/policy-and-analysis/
reports/Pages/masters-with-
a-purpose.aspx
**Vitae (2009) What do 
researchers do? First 
destinations of doctoral 
graduates by subject. 
Available online at: https://
www.vitae.ac.uk/vitae-
publications/reports/what-
do-researchers-do-wdrd-by-
subject-vitae-jun-2009.pdf/
view
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will be focused on career progression and the quality of 
education and training, thus raising some relevant issues 
for postdoctoral career progression and undergraduate 
education. 
Fellows and staff
Reflections on career development from fellows 
and staff:
“It gave us lectureships, and the chance for 
independence, at a time when we wouldn’t have got 
them otherwise.” 
(Interviewee FS2, non-IMB centre)
“The fellowship, again, it just…it helps people that 
have in vivo skills get themselves established, which 
is really important, and again, in vivo research is so 
extremely expensive that just any support you can 
get is vital.” 
(Interviewee FS8, IMB centre) 
“I’m currently at lecturer level, my grant is coming 
to an end and I don’t have any… so my postdoc has 
finished and I don’t have any PhD students. My 
research is at risk of failing entirely if I can’t get 
another grant.” 
(Interviewee FS4, IMB centre)
The quotes above illustrate the positive effect of the IPF 
on individual careers, but also the challenges that face 
in vivo researchers. All three of these interviewees (and 
many others) were grateful that the IPF initiative had 
enabled them to obtain positions that they believe they 
would not have obtained otherwise. Due to the challenges 
of in vivo research, an intervention that specifically 
appointed in vivo researchers was invaluable in allowing 
those appointed to acquire fellowships and lectureships. 
Challenges include: the financial cost, regulatory 
requirements and ethical concerns of in vivo research, 
and that it is perceived to be unfashionable (compared 
with molecular biological research for example) and 
has lower outputs in terms of publications compared to 
other areas of biological research. These challenges make 
ongoing support to maintain this work vital. Interviewee 
FS4’s problems highlight this, and they also express the 
difficulties of starting a research group if the continuity 
of postdoctoral researchers and PhD students in the lab is 
broken.
Two staff interviewees commented on the importance 
of the IMB centre as a support network, in terms of 
helping them to navigate the UK regulatory system and 
mentorship to boost their confidence as a researcher. One 
interviewee who had moved to the UK believed that the 
more competitive research environment in the UK helped 
improve their research. 
The fellowships have been 
praised by those who held 
them for providing security 
and freedom to conduct 
research. The graduated 
increase in teaching time 
meant that by the end 
of the five years of the 
fellowship the holders 
were fully prepared for the 
transition to the teaching 
load expected of a lecturer, 
and felt able to make the 
transition without their 
research suffering. 
PhD students attached 
to new fellowships and 
lectureships enabled 
the holders of these 
positions to produce data 
for publications and to 
obtain new grants. PhD 
students funded in part by 
the IPF were also attached 
to laboratories where the PI was not appointed by the 
IPF initiative, and were able to add to the research of 
the laboratory and leverage further funds. Additional 
competitive training grants were received by IMB centres 
from the MRC, BBSRC, British Pharmacological Society, 
Wellcome, the British Heart Foundation (BHF) and Cancer 
Research UK (CRUK). 
Of the 15 respondents who hold grants, 14 (93%) believe 
that their prior IPF-supported work enabled them to win 
these grants. Many interviewees attributed their later 
grant success to the initial IPF support: “they believe that 
we’re capable of doing in vivo research because we’ve had 
grant funding to support that previously” (interviewee FS5, 
IMB centre).
Master’s and PhD training
Feedback on Master’s and PhD training:
“It was a really broad skill set, it was quite 
comprehensive as well, and I didn’t think we 
probably quite realised that until we finished and 
we were working with other people who had done 
Master’s and various different bits and pieces, and 
we’re working alongside them, and you realise 
you’ve actually got far more skills than they do.” 
(Interviewee MP4, IMB centre) 
“It did produce five papers, three of which were very 
high impact, so that’s obviously facilitated my career 
thereafter.” 
(Interviewee MP1, non-IMB centre)
RECOMMENDATION
Provide support for early 
career researchers
Learned societies 
and partners should 
make a new strategic 
commitment to fund 
pump-priming grants for 
early career researchers. 
Higher education 
institutions, research 
councils, learned and 
professional societies 
should recognise the 
importance of explicitly in 
vivo research fellowships, 
and should work 
together to ensure that 
these positions can be 
financially supported and 
sustained.
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In the questionnaire 
responses, 16 out of 
25 respondents (64%) 
considered their in vivo 
training to have been 
important in securing their 
current role. Respondents 
agreed that the IPF 
encouraged their skills in 
experimental design (19 
out of 25, 76%), new in vivo 
techniques (23 out of 24, 
96%) and animal welfare 
and the 3Rs (21 out of 25, 
84%). For those for whom 
it is applicable, 50% (7 
out of 14) have grants to 
support their research.
The training received by 
Master’s students was 
highly rated by them, with 
a broad-based education 
in the different areas 
of in vivo research accompanying a strong focus on 
experimental design and animal welfare. The laboratory 
rotations in the Master’s courses enabled students and 
prospective supervisors to assess each other in advance 
of working in a laboratory during a PhD. This was thought 
to be valuable by students and PIs alike, and aided 
progression from Master’s to PhD. Furthermore, it was felt 
that the in vivo skills Master’s training helped students 
to acquire competitive PhD places. Visits to industrial 
sites and speakers from industry were valued by former 
Master’s students..
The PhD training at IMB centres was thought by those 
who received it to be an excellent preparation for 
research: “the training was very clearly motivated towards 
making you a very useful PhD student to the research 
group you went to, which on reflection I think was very 
good” (interviewee MP5, IMB centre). It also enabled 
researchers like interviewee MP1 to establish a track 
record of publications, which helped them to obtain 
positions after completion. Some supervisors offered 
the view that it would be valuable for PhD students to be 
provided with funding to enable them to learn techniques 
from experts.
There are examples of 
researchers appointed as a 
result of the IPF initiative 
who have brought new in 
vivo skills that they learned 
during their Master’s and/
or PhD to laboratories, 
providing the laboratory 
and other researchers in 
it with new collaborative 
possibilities and new 
modes of conducting 
research. 
Of the Master’s and PhDs 
students who have not 
gone on to careers in 
research, many are in a position where they are using 
either some of the in vivo skills that they learned in their 
postgraduate training, or the more generic skills (for 
example, communicating to a lay audience or writing) 
that they learned as a result of doing a PhD.
Postdoctoral Researchers
A large number of concerns were raised about the 
transition from postdoctoral research to independence, 
though this is not confined to in vivo research. These 
concerns were raised by both female and male 
interviewees, and yet the instability of post-PhD 
academic employment disproportionately discouraged 
female PhD holders from pursuing further research in 
academia. 
Pump-priming grants were relatively small sums of 
money that allowed holders to develop and use new 
models, in one case with the effect of being able to form a 
collaboration that has led to the awarding of a fellowship 
and a permanent lectureship. 
Undergraduates
The IPF support for undergraduate modules with in vivo 
education components was another example of the 
leverage enabled by relatively small amounts of funding. 
Departments used this external funding as validation for 
the course to justify its continuation and the maintenance 
of university support for it. 
The short residential courses run by the British 
Pharmacological Society and The Physiological Society 
were highly rated by students who participated in 
them, and the researchers involved in running them 
are enthusiastic about their value. Similarly, academics 
involved with undergraduate in vivo modules as part of 
the taught curriculum are effusive about them. Data from 
one such undergraduate course, at King’s College London, 
indicates that many of the students who participated 
have gone on to intra-mural year projects with in vivo 
content. Unfortunately, there are wider concerns about 
the supply of industry placements for undergraduate 
students. 
Students of both the short-courses and in vivo 
undergraduate modules reported that these enhanced 
their employability.d Depending on whether the 
undergraduate module was run under delegated 
authority or an educational project licence, the 
undergraduate education courses cost the British 
Pharmacological Society roughly six to nine times 
less, per student, than the cost of the short residential 
courses.e 
RECOMMENDATION
Create innovative 
resources and approaches
The community 
of educators and 
educational institutions 
should cooperate towards 
developing innovative 
education and training 
resources and approaches 
to prepare students for 
postgraduate research 
and/or employment. 
These approaches and 
resources should be 
developed in alignment 
with agreed learning 
outcomes and set up with 
impact assessment in 
mind.
RECOMMENDATION
Support undergraduate 
education modules
The British 
Pharmacological Society 
should continue to 
provide part-funding for 
undergraduate education 
modules, to foster 
stability and security 
for the continuation of 
entry level in vivo skills 
education. 
d In data obtained from 65% (93 out of 143) graduates enrolled on the 
University of Leeds Level 6 in vivo education module BMSC3126 from 2005–
2015, 77% of all respondents agreed or strongly agreed that the practical 
skills gained through the module had been beneficial to their subsequent 
career, and 99% agreed or strongly agreed that the employability skills 
developed during the module had been beneficial to their subsequent 
career.
e This estimate uses figures from 2013–14, the final year of full funding. 
For modules run under delegated authority, full animal and consumables 
costs were covered. For modules run under an education project licence, 
a contribution was made to the cost, but the rest was covered by the 
university.
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What is delegated authority?
The guidance to A(SP)A permits licensees to: “Delegate 
tasks which form an integral part of the regulated 
procedures that you are authorised to perform to 
assistants under your control who do not themselves 
possess the requisite personal licence authority. The 
tasks must not require technical knowledge or skill.”
As such, students can participate in, and gain hands-on 
in vivo practical experience of, most procedures currently 
undertaken under educational project licences through 
the use of delegated authorities. These include the 
use of freely moving animals, anaesthetised animals 
and ex vivo preparations, for example:
  Psychopharmacology: Student placement of 
animals in behavioural arenas and their scoring of 
animal behaviours; any pharmacological agents 
being administered by the supervising licensee.
  Diuretic modulation of renal function: Student 
placement of animals in metabolic chambers, 
collecting and analysing the excreted urine; any 
pharmacological agents being administered by 
the supervising licencee.
  Pharmacological modulation of physiological 
responses in anaesthetised preparations: 
Student injection of pharmacological agents 
through previously implanted cannulas and 
their measurement of changes in physiological 
parameters or reflexes. The supervising licensee 
is responsible for the surgical preparation of 
the animal, insertion of catheters and other 
measurement devices, and the induction and 
maintenance of anaesthesia.
  Assessment of physiological function and 
reflexes in ex vivo preparations. Once the 
supervising licensee has set up the preparation, 
it falls outside of the Act. Students can, for 
example, administer pharmacological agents, 
electrically stimulate nerves and record changes 
in physiological parameters or reflex function.
These can be complimented by hands-on training 
in procedural skills performed using models or 
cadavers, for example:
Injection technique: Using a model animal 
or cadaver, students inject intraperitoneally, 
subcutaneously, intravenously or by gastric gavage. 
When using a cadaver, students can inject dye and 
then undertake a dissection to check the location 
of their injection. This can be useful for relating the 
anatomy of the animal to potential complications 
associated with injection procedures.
Training in surgical techniques (e.g. blood vessel 
cannulation and tracheotomy): Students are 
given a cadaver and following guidance undertake 
cannulation of an artery and vein and perform a 
tracheotomy. Students are taught about aseptic 
technique and good practice for surgical procedures.
Acknowledgement: With thanks to Dr Emma Robinson (University of Bristol) and 
Dr Dave Lewis for their input.
Students who participated in the undergraduate in vivo 
modules supported by the IPF were invited to complete a 
feedback survey after their courses. Free text responses 
from students indicate they valued taking part for a range 
of reasons, including feeling more confident, gaining 
insight on a potential career working in animal research, 
improved awareness of the ethical considerations of in 
vivo work and gaining knowledge of research techniques 
and animal physiology. However, the two most commonly 
cited reasons were the opportunity to get hands-on 
experience and to develop practical skills. 
The IPF support for 
undergraduate modules 
contributes towards the 
cost of animals and Home 
Office licence training 
and licences (where 
applicable) and the costs 
of running the courses. 
Exposure to licenced 
procedures, whether 
hands-on or via delegated 
authority, is not primarily 
about producing people 
with in vivo skills but about 
exposure to in vivo work, 
to ensure that students 
can make an informed 
decision about embarking 
on further in vivo education and training. It is not 
clear whether continued support for licences for 
undergraduates is necessary to maintain high-quality 
in vivo education. Several interviewees suggested 
that the same educational learning outcomes are 
achieved through the use of a combination of delegated 
authorities, demonstrations, cadavers and e-learning 
tools to provide the exposure to in vivo work. As this 
would cost considerably less, it may help retain courses 
with some kind of in vivo component allied to some 
hands-on practical experience. It would also advance the 
aims of the 3Rs by using fewer live animals to achieve 
similar learning outcomes. 
The evaluation has opened up the issue of undergraduate 
education as a key factor in the future development 
and sustainability of in vivo research. At the stakeholder 
workshop, several participants raised concerns that in 
relevant undergraduate degrees such as pharmacology 
and biomedical sciences, there was not sufficient 
introduction to the nature, principles and practices 
involved with in vivo research. The importance of 
exposing students to in vivo research and explaining its 
purposes was emphasised by multiple participants, albeit 
for different reasons. Some stressed the importance 
of making students aware of the possibilities of in vivo 
research, thereby exposing them to an area of research 
that they may have otherwise not been properly aware. 
Others saw undergraduate education as a suitable place 
for intervening to address the perceived problems 
concerning experimental design and practice in 
biomedical research, and further improve standards 
RECOMMENDATION
Develop core learning 
outcomes
Educators and employers 
in the in vivo community 
should work together and 
lead the development 
of clear core learning 
objectives for the in 
vivo sciences, including 
experimental design, 
statistics, animal welfare, 
the culture of care, ethics 
and the 3Rs. 
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of animal welfare in research.16,17,18 There was broad 
agreement that in vivo work and principles of good 
experimental design, statistics and animal welfare should 
be introduced earlier into undergraduate studies, and be 
returned to throughout the course of the degree.
4.3. RESEARCH PRACTICE AND 
OUTCOMES
Support by the IPF enabled many of the recipients to 
develop innovative programmes of research, with some 
developing new animal models of disease and injury, or 
adapting existing ones to new purposes. Researchers 
supported by the IPF have published widely, and some 
have published papers with high numbers of citations 
in journals that encompass in vivo and non-in vivo work. 
In surveys of academic fellows (conducted by the IPF in 
2009) and lecturers (conducted by the IPF in 2011), 7 out 
of 20 had received prizes for their research or teaching. 
The fellows and staff questionnaire respondents from 
2015–16 worked across many areas of research, mainly 
neuroscience or electrophysiology but also cardiovascular 
research, endocrinology and immunology, with two 
respondents each working in two different fields. While 
the researchers who responded mainly worked with rats 
and mice, they also worked with (non-human) primates, 
humans, guinea-pigs, pigs, rabbits, zebrafish and 
amphibians, such as Xenopus laevis. 
Fellows attributed the development of productive new 
models and research to the security of the fellowships. 
This security enabled them to take risks, for instance, 
conducting research that might not have guaranteed 
publishable results. The pump-priming grants also 
enabled researchers to develop new experimental 
models. The extra funding available allowed them to 
design experiments that produced results with more 
translational potential than more limited experiments 
may have done.
Research quality and the 3Rs
13 out of 16 (81%) questionnaire respondents who were 
appointed as a fellow or staff agreed that the IPF had 
enabled them to work towards the aims of the 3Rs. 
The transposition of EU Directive 2010/63/EU and the 
16 Begley CG and Ellis LM (2012) Drug development: Raise standards for 
preclinical cancer research, Nature, Vol. 483 No. 7391: 531–533.
17 Begley CG and Ioannidis JP (2015) Reproducibility in Science: Improving 
the Standard for Basic and Preclinical Research, Circulation Research, Vol. 
116 No. 1: 116–126.
18 Macleod MR et al (2015) Risk of Bias in Reports of In vivo Research: A 
Focus for Improvement, PLoS Biology, Vol. 13 No. 10: e1002273.
rewriting of the guidance to A(SP)A, along with the 
establishment of the NC3Rs make it difficult to identify 
the precise role that the IPF intervention has played in 
improving standards of animal welfare and care. There 
are, however, numerous concrete examples of IPF-funded 
researchers or researchers within IMB centres who have 
made improvements to research practices that have 
improved the 3Rs. These include the development of 
rodent handling techniques to lower their stress levels 
by a group at the University of Liverpool IMB centre, and 
the introduction to a laboratory of imaging techniques 
that reduce the number of animals used in experiments 
by a former Imperial College London IPF-supported PhD 
student. A fellow supported by the IPF has participated 
in the development of the Experimental Design Assistant 
pioneered by the NC3Rs. Another has replaced the use 
of wires to track neural activity in rats with wireless 
transmitters that are less stressful for the animal, 
and generate considerably more data which enables a 
reduction in the number of rats used. At one IMB centre, 
a new animal model was developed which replicates the 
co-morbidity associated with human manifestations of a 
disease: the model was developed by one of the lecturers 
appointed as a part of the IMB centre bid, in conjunction 
with a PhD student supported by the IPF. 
19 out of 25 questioned (76%) who received IPF support 
as a Master’s and/or PhD student, agreed that the IPF 
enabled them to develop their skills and competency in 
experimental design, 23 out of 24 (96%) agreed that the 
IPF enabled them to develop their skills and competency 
in new in vivo techniques, and 21 out of 25 (84%) agreed 
that the IPF enabled them to develop their skills and 
competency in animal welfare and the 3Rs. 24 out of 25 
respondents (96%) affirmed that their training had helped 
them work towards the aim of the 3Rs: “The 3Rs were 
instilled in us from the very start and we received continual 
training and communications via the course tutors, the animal 
units and the named vets.” Interviews have confirmed this 
focus on experimental design and the 3Rs, particularly in 
Master’s courses, although these elements were not a key 
feature of the Master’s offered at the University of Glasgow. 
One dissenting questionnaire respondent commented, 
“There is still an over-reliance on employing large scale animal 
studies, often with limited rationale.” 
Examples have been given of an approach to in 
vivo education provided by IPF-supported staff at 
undergraduate and Master’s level, which sets particular 
research problems to students, who then have to design 
appropriate experiments. As a former Master’s student 
at an IMB centre put it, “We usually had to design our 
experiments with the idea of animal welfare and numbers 
and the whole process behind it, which helped a huge 
amount during the PhD” (interviewee MP4). A lecturer at a 
non-IMB centre institution relates: “In particular practical 
designs I wanted students to understand the design of in vivo 
experiments, power calculations and so forth. So I gave them 
a question which was actually a part of my research I had 
done” (interviewee FS11). Another lecturer at an IMB centre 
institution commented that teaching the 3Rs to students 
prompted personal reflection: “[Teaching] made me go 
back and revisit the things that I’d gone through and maybe 
got me a little more 3Rs orientated” (interviewee FS7).
Pump-priming grant recipient on how the money 
was useful:
“This sum of money actually made me do what I 
wanted to do and what I think is translationally 
relevant, rather than go for the cheap way to do 
things, but not proper way of doing things.” 
(Interviewee FS11, non-IMB centre)
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Sources of expertise
As well as being the hub for animal research and sitting 
on the Animal Welfare and Ethical Review Body, the 
Experimental Officer at The University of Manchester 
has been involved in various projects, including a 
tissue-sharing resource which seeks to maximise the 
use of tissues from euthanized animals, and running 
an experimental design course with a colleague. They 
described a key part of their job as, “Ensuring that 
everybody who’s using animals has an absolute knowledge 
of experimental design, and they are therefore able 
to refine their experiments as far as possible.” The 
Experimental Officer at the University of Manchester 
was a conduit for all animal work. As a consequence, 
clinicians approached the IMB centre at Manchester 
to conduct translational research, and collaborations 
were established to test treatments in animal models. 
Several interviewees noted the importance of non-
research technical staff or technologists as an actual 
or possible source of expertise for effective practice 
concerning procedures and welfare, and believed that in 
their institutions (with the exception of the University of 
Manchester) some form of intervention to support the 
technical side was missing from the IPF. As universities 
rather than research councils fund technical staff, a 
different model of collaborative funding would be 
required to support them. 
Translational research
Having in vivo researchers alongside non-in vivo researchers 
has enabled those researchers to take their research closer 
to the clinic. The capacity of a laboratory to do in vivo work 
has therefore enabled groups to take the next step towards 
working with clinicians. Having a teaching hospital with 
researcher clinicians nearby is an advantage to researchers 
in terms of the informal discussions which can guide 
research design and improve the chances of clinically-
relevant knowledge being produced. One interviewee cited 
the transformation of their perspectives towards a more 
translational approach over the course of the period that 
their IMB centre existed. 
Improving standards
Staff appointed as a result of the IPF have been involved 
in community-wide efforts to improve standards of 
research, for instance by participating in NC3Rs projects 
and the setting of journal standards. These standards 
include requirements on the reporting of methods, 
experimental design, use of power calculations to 
identify proper sample sizes, and the use of statistics. 
4.4. NETWORK, COLLABORATION, 
DISSEMINATION
Networks and hubs
There were strong 
networks fostered at the 
level of individual IMB 
centres within institutions. 
Deliberate and successful 
attempts were made to 
create communities of 
Master’s and PhD students 
trained within IMB centres. 
Researchers in some cases 
continue to identify with 
them even after they 
have formally ceased. A 
number of joint courses 
were established between 
centres, for example a 
joint telemetry course 
involving King’s College 
London and Imperial 
College London. These 
two centres, together with 
University College London 
and the Universities of 
Cambridge and Oxford, 
formed a ‘Global Medical 
Excellence Cluster’, 
which works closely with 
the pharmaceutical 
industry to support 
integrative physiology and 
pharmacology.
Nationally, there was 
little sense of a common 
identity or network of the 
IPF-supported researchers, 
although three national 
events were held.f The 
lack of a national network 
inhibited the fostering of a 
stronger in vivo community. 
The IMB centres did not operate as hubs in terms of formal 
arrangements with nearby universities. This was at least in 
part due to the lack of funds for this, and the difficulty of 
getting universities to work together. Two London-based 
interviewees noted that the IMB centres were too short-
lived to properly establish themselves as longer-term hubs. 
Dual-institution arrangements worked to a certain degree 
over the lifespan of the IPF but, some limited training and 
research collaboration aside, have not been sustained. 
The Experimental Officer role provides a point through 
which all in vivo work in the institution flows. They are 
therefore able to establish collaborations, advise on good 
RECOMMENDATION
Nurture networks of  
good practice
The in vivo sciences cross 
a range of disciplines, 
and networks of good 
practice should be 
cross-cutting but deal 
with specific areas of 
need such as: building 
and/or encouraging 
participation in in vivo 
research and education 
networks, signposting 
them to people first as 
undergraduates and 
then throughout their 
careers; supporting 
the development of 
online open access 
repositories showcasing 
course materials 
that use innovative 
approaches to learning 
in in vivo pharmacology; 
maintaining and 
developing national 
knowledge-sharing 
networks sharing good 
practice to advance 
excellent research with 
high welfare standards; 
making grants available 
to support PhD students 
learning a particular in 
vivo technique in another 
laboratory. 
f These events included a meeting and visit to a GSK facility in Stevenage 
in 2007, a two-day meeting in London in 2009, and a meeting at The 
University of Manchester on welfare involving all IMB centres and run in 
collaboration with the NC3Rs in 2011.
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practice, and try and ensure adherence to the highest 
standards of research and animal welfare. As the Named 
Information Officer (NIO) and Named Training and 
Competency Officer (NTCO), the Experimental Officer is in 
a good position to ensure as much as possible that current 
good practice is adopted as well as disseminated. 
The Business Development Manager (funded by the North 
West Regional Development Agency) at Manchester-
Liverpool and the Industrial Impact Fellow (funded by 
BBSRC) at King’s College London were successful in forging 
collaborations between individual researchers and groups 
and industry, in addition to obtaining Collaborative Awards 
in Science and Engineering (CASE) studentships, which are 
PhD projects run in collaboration with industry. 
Disseminating good practice
Many interviewees 
expressed the view that 
current good practice is not 
well shared on a national 
level. A few expressed 
the view that it is not 
adopted well, rather than 
disseminated poorly. A few 
meetings aside, the IPF 
missed an opportunity to 
develop a network of animal 
researchers across the UK, 
which may have assisted 
in the dissemination of 
effective practice. 
The Master’s courses 
and other courses which 
operated in large part due 
to the IPF support enabled 
the education of students 
in current good practice, 
both in experimental 
design and the 3Rs, and 
also encouraged them to 
think about the best way 
to conduct experiments rather than simply apply a rote 
method or protocol. In establishing centres of excellence 
with strong internal networks and a high concentration of 
in vivo researchers, the IPF was successful in establishing 
the means for strong local sharing of current good 
practice. 
Facilitating collaboration
All 17 fellows and staff who responded to the 
questionnaire had established collaborations with 
scientists from other groups and disciplines. Eight 
respondents (47%) specifically cited collaborations 
with researchers at pharmaceutical or biotechnology 
companies, four (24%) specifically cited collaborations 
with clinicians or other healthcare providers, and one 
with another industry (food). In interviews, some 
researchers commented that it was their visibility as 
in vivo researchers appointed by the IPF initiative that 
initially fostered collaborations. The prominence of 
the IMB centre also directed attention towards the 
researchers working in it. As one senior member of staff 
in an IMB centre put it, “Everybody knew what [the] IMB 
centre was within the university, everybody knew who 
to go and ask.” In some cases, the collaborations came 
about because they had in vivo skills that could contribute 
towards a specific project. 
As cited above, the 
Business Development 
Manager at The University 
of Manchester and the 
Industrial Impact Fellow 
at King’s College London 
were successful in helping 
academic researchers to 
establish collaborations 
with people and 
companies in the private 
sector. Additionally, 
the Experimental 
Officer helped to forge 
collaborations between 
life science researchers 
and clinical researchers. 
Responding to concerns 
about the cost to industry 
of engaging with academic 
researchers (such as the 
cost of funding a PhD 
studentship which may 
not provide the results 
desired by the industrial funder), and the institutional 
barriers towards formal collaboration, the Industrial 
Impact Fellow developed several initiatives. One 
initiative deemed to be a success was ‘Find Your Ideal 
Partner,’ in which funds were provided to academic 
researchers to conduct small projects that could serve as 
feasibility experiments for potentially larger projects in 
collaboration with industry. One less successful initiative 
was developing a ‘fee-for-service’ model for services 
provided to industry by academics, which has so far not 
generated regular business, but is still ongoing.
Initiatives focusing on particular problems faced by 
industry, involving discussions between academic 
researchers and industry researchers, offer the 
potential for lowering the barriers to cooperation and 
collaboration. One example comes from the University 
of Bristol, where ‘Industry Day’ events were organised 
in 2015 and 2016, at which industrial and academic 
researchers participated in sessions focusing on industry 
challenges and how academic researchers could help.
Clinical collaborations cited by researchers, which 
enabled them to alter the way in which they designed 
their research to make it potentially more translatable, 
tended to depend upon proximity. This is especially 
true for the more informal collaborations based on the 
sharing of expertise. Academic researchers found formal 
collaborations with clinicians and the NHS less easy to 
initiate than with industry, but one of the IPF-supported 
fellows did secure a fellowship concerning translational 
research from the NHS. 
Dissemination of current 
good practice by Fellows 
and Staff:
11 out of 16 (69%) agreed 
that the IPF initiative 
had encouraged them to 
disseminate current good 
practice in experimental 
design.
12 out of 16 (75%) agreed 
that the IPF initiative 
had encouraged them to 
disseminate current good 
practice in animal welfare 
and the 3Rs.
12 out of 16 (75%) agreed 
that the IPF initiative 
had encouraged them 
to disseminate current 
good practice for in vivo 
techniques. 
RECOMMENDATION
Foster collaborations 
across academia, 
industry and the NHS
Research collaborations 
involving in vivo 
researchers in academia, 
industry and the NHS 
need to be supported, 
with obstacles to 
cooperation identified 
and addressed. Studies 
and evaluations should 
be conducted to inform 
and facilitate long-term 
links, collaborations and 
relationships between 
academic education, 
training and research, 
industry and the NHS.
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Supporting outreach
Participation in outreach activities was a key stipulation 
for the receipt of support from the IPF. 12 out of 16 fellows 
and staff questionnaire 
respondents (75%) had 
engaged in outreach 
activities, many of which 
involved school visits. 9 
out of 16 (65%) are still 
involved in outreach 
activities; time constraints 
and the lack of value 
placed on such activities 
by the university were 
a limitation for some. 
76% (19 out of 25) of 
Master’s and PhD students 
participated in outreach 
activities of varying types, 
which are listed in the 
following boxes:
Activities of postgraduates supported by the IPF: Activities of fellows and staff supported by the IPF:
Supervision of sixth form students for a summer project Drug testing at the London 2012 Olympic Games
Helping out with open days by talking about research and 
explaining complex ideas
Involvement in science on the International Space Station 
initiatives
Involvement in scientific policy: communication with 
government and the public about animal research
BBSRC Schools Regional Champion
Volunteering for Understanding Animal Research (UAR) School visits
School visits and talks Running small workshops at science fairs and museums
Participation in careers fairs on studying science (women 
in Science, Technology, Engineering and Mathematics or 
STEM)
Giving public lectures
Involvement in ‘Pint of Science’ event Made videos for UAR
Social media based campaigning Putting on work experience weeks for year 10 students
Involvement in museum events STEM ambassador 
Giving public talks or lectures Volunteer for UAR
Serving as a STEM ambassador Pint of Science
Scientific advisory committee member Organising IMB centre showcase event
Table 3. Description of outreach and engagement involvement reported by students and staff supported by the IPF.
RECOMMENDATION
Recognise and support 
engagement work
Public engagement 
and student outreach 
should be supported and 
encouraged by higher 
education institutions 
and learned societies as a 
core activity of academic 
researchers, advancing 
the commitments 
contained in the 
Concordat on Openness 
on Animal Research.
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5. RECOMMENDATIONS
PRINCIPLES
The IPF successfully brought together multiple stakeholders to 
leverage the initial £4 million into a sum of £22 million. The steering 
committee approach incorporating stakeholders enabled a consensual 
approach to strategic decision-making. Future initiatives, including 
those recommended in the course of this report, should be based on 
these principles of partnership and collaboration. From the findings of 
the evaluation and related recommendations, we have extracted four 
common principles to underpin future work and initiatives: 
Lessons from the IPF: guiding principles for future initiatives
We now explore the ten recommendations in more detail, explaining 
the context and evidence for their proposal, and detail the follow-up 
actions suggested for their implementation.
Responsive leadership
Recognising that organisations, 
including the British Pharmacological 
Society and partners, need to take 
flexible and responsive leadership 
roles in facilitating community 
engagement, brokering resources 
and taking a long-term view of  
in vivo skills needs.
Embedded partnerships
Ensuring that long-term 
collaborative relationships 
are built between academic 
researchers and research 
institutions and researchers and 
institutions operating outside 
of academia, for instance in 
industry or the NHS.
Open pathways
Building collaborative and 
sustainable ways of working that 
recognise, value, develop and use 
the diverse routes and roles to 
and within in vivo research. 
Networked communities
Creating connected  
communities of educators  
and shared educational  
resources for good practice  
in in vivo research. 
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RECOMMENDATION 1:  
DEVELOP CORE LEARNING 
OUTCOMES
Educators and employers in the in vivo community 
should work together and lead the development 
of clear core learning objectives for the in vivo 
sciences, including experimental design, statistics, 
animal welfare, cultures of care, ethics and the 3Rs. 
These outcomes should be integrated across the 
biosciences, and should be reinforced throughout a 
student’s undergraduate and postgraduate career.
Contexts
The Master’s courses provided by the IMB centres 
featured a strong focus on experimental design and the 
3Rs. Students were set particular research problems, and 
were tasked with designing appropriate experiments. 
Multiple respondents emphasised the need for these 
aspects to be included in undergraduate education 
to ensure that students are able to make informed 
choices about their futures, as well as being aware of the 
principles of in vivo research, animal welfare and good 
experimental design and practice, ahead of entry into 
postgraduate study or employment. 
In the case of statistics, the Level 5 Animal Models of 
Disease and Injury module at King’s College London led 
to a new way of teaching statistics to biological sciences 
undergraduates being developed that made learning 
the principles and practice of statistical analysis more 
accessible to them.
Actions
There is ongoing debate about the kind of education 
and training that should play a role in undergraduate 
pharmacology. There is agreement that undergraduate 
exposure to in vivo research is vital for making students 
aware of what it entails and for helping them to make the 
emotional and intellectual steps required of prospective 
in vivo researchers. Education about in vivo science 
needs to be provided earlier in undergraduate studies, 
with a wider introduction of animal research and in vivo 
techniques to Level 4 undergraduates, so that they 
understand the concepts and practicalities of in vivo 
research, and to improve employability. Employability 
should not just focus on prospective academic 
researchers, but should also equip students to navigate 
the current industry environment.
The British Pharmacological Society, in collaboration with 
multiple partners, should therefore develop learning 
objectives that encompass these aspects and other needs 
of relevant stakeholders, for instance with academic, 
technical, industrial, clinical and learned society input. 
The learning objectives should be congruent with (and, 
possibly, cross-referenced to) the Subject Benchmark 
Statements outlined by 
the Quality Assurance 
Agency (QAA). The learning 
objectives should be 
broad enough to ensure 
that there is enough 
commonality or core 
objectives in Level 4 and 
Level 5 undergraduate 
programmes to allow 
the development and 
sharing of resources 
(see Recommendation 
5), but allow individual 
institutions to develop 
bespoke courses suited 
to their own strengths 
and areas of application. 
The development of the 
learning objectives should 
draw upon the experiences 
of those who have 
previously participated in 
efforts to establish core 
curricula in pharmacology 
(see the examples to the 
right). 
Undergraduate education 
on topics such as 
experimental design and 
animal welfare should 
be particular to the skills 
needs and disciplinary 
content being taught. For 
example, like the King’s 
College London module 
mentioned, statistics 
teaching should be 
adapted to needs of life 
sciences undergraduates, 
rather than starting from a 
high level of statistical theory. 
A potential model that could form the basis for the 
development of these learning outcomes is for all Level 
4 undergraduate students taking relevant degrees (such 
as pharmacology and biomedical sciences) to receive 
education about what in vivo research involves and is 
for, and the importance and principles of experimental 
design, welfare and ethics. Online resources such as 
videos may be used, and data from real experiments 
(perhaps those depicted in the videos, also simulations 
on websites such as www.virtualpharmacologylab.com) 
could be used in class exercises. The smaller number 
of Level 5 students may then participate in a course 
operated under delegated authority, and thus have more 
hands-on experience. For Level 6 students, a course run 
under delegated authority may be run, or if there is a 
sufficiently robust rationale, one involving education or 
training that requires them to obtain a personal licence. 
Higher education institutions should be asked to make 
explicit to students the opportunities to gain a robust 
education in in vivo sciences, for example by providing 
Examples of prior 
initiatives to develop 
core curricula:
2007–2008: Formulation 
of MSc in Safety 
Pharmacology post-
2007 ABPI/Biosciences 
Federation in vivo 
sciences report – most of 
courses that adopted this 
have now ceased due to 
lack of demand and/or 
funds.
2011: Development 
of Integrated 
4-year Master’s in 
Integrative Physiology 
& Pharmacology for 
Research, which is still 
running at King’s College 
London.
2011: Royal Society 
of Biology pilot 
accreditation of in vivo 
sciences undergraduate 
degree (post-“Blueprint 
for the Life Sciences” 
report of the Office for 
Life Sciences) – these 
accreditation criteria 
are now broader and not 
explicitly in vivo.
2013–2014: Development 
of Royal Society of 
Biology accreditation 
criteria for in vivo MSc 
– this did not proceed 
beyond planning stage.
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key information on their courses, such as how much 
money they provide for Level 6 projects, employability 
data, contact time (including time in the laboratory) and 
data relating to placements. The British Pharmacological 
Society and other learned societies could encourage 
course organisers and admissions tutors to use such data 
in undergraduate recruitment. Clarity around learning 
outcomes from educators and employers would help 
tailor appropriate resources and inform their delivery. 
RECOMMENDATION 2:  
CONDUCT RESEARCH ON 
EDUCATIONAL OUTCOMES
Higher education institutions and learned societies 
should conduct research on the educational 
outcomes of different education and training routes 
and methods, and should forge ways to ensure 
that data collection and analysis are supported and 
based on common standards.
Contexts
The importance of, in particular, undergraduate education 
and training to achieve the aims of improving the supply 
and quality of people trained in in vivo techniques, was a 
feature of responses from interviewees and participants 
at the stakeholder workshop. There was disagreement, 
however, on the models of education and training that are 
most effective. These disagreements cannot be resolved 
in the absence of systematic data collection and analysis 
of the outcomes of different models and examples of 
education and training. The Wakeham Review of STEM 
Degree Provision and Graduate Employability19,20 has 
called for “a greater degree of granularity around data 
on graduate outcomes so that we can construct a more 
nuanced understanding of the factors that really make a 
difference,” and in response the British Pharmacological 
Society has made suggestions about ways to improve data 
collection. Additionally, the Higher Education Statistics 
Agency is conducting a review of the data it collects on 
graduate destinations and outcomes.21 
Actions
The effectiveness and outcomes of Level 5 and Level 6 
undergraduate courses that incorporate personal licences 
and those that do not should be evaluated, and there 
should be sharing of experiences on the role delegated 
authority could play in undergraduate education.
19 Wakeham Review of STEM Degree Provision and Graduate 
Employability (2016). Available online at: www.gov.uk/government/
uploads/system/uploads/attachment_data/file/518582/ind-16-6-
wakeham-review-stem-graduate-employability.pdf. 
20 British Pharmacological Society (2016) Response to the Wakeham 
Review. Available online at: www.bps.ac.uk/about/policy-positions/
consultation-responses/articles/response-to-the-wakeham-review.
21 HESA (2015) Review of Data on Destinations and Outcomes for Leavers 
from HE. Available online at: www.hesa.ac.uk/pr/3686-review-of-data-on-
destinations-and-outcomes-for-leavers-from-he.
There should be regular curriculum reviews and 
formalised exit surveys and follow-ups with students 
supported by the British Pharmacological Society 
and others in conjunction with relevant university 
departments. The means to conduct this work and contact 
students should be in place from the start of their course, 
to enable the collection and analysis of quantitative data 
concerning the impact and outcomes of particular courses 
and initiatives. The British Pharmacological Society could 
assist in the efforts of relevant university departments 
to collect and analyse data, including providing some 
common platforms for data entry and analysis to ease 
the burden on universities and allow comparability of 
data. Issues around data protection and access to contact 
details will need to be explored. 
Furthermore, the British Pharmacological Society and 
partners should support the conducting of a regular 
survey of in vivo education and training, track the careers 
of the IPF-supported students, and develop and publish 
career case studies.
RECOMMENDATION 3:  
SUPPORT UNDERGRADUATE 
EDUCATION MODULES
The British Pharmacological Society should 
continue to provide part-funding for undergraduate 
education modules, to foster stability and security 
for the continuation of entry-level in vivo skills 
education. 
Contexts
Undergraduate education and training is a key point 
of intervention in the development of high quality 
researchers and scientifically-trained employees. It 
exposes students to in vivo research, which enables 
them to make a more informed decision about whether 
to pursue postgraduate study or employment in that 
field, as well as potentially equipping them with the 
knowledge and skills that will enable them to conduct 
research with high standards of welfare and reproducible 
results. Evaluations of short courses by participants rate 
them highly, but these courses are expensive to run. 
Additionally, well-resourced and organised undergraduate 
education modules supported by higher education 
institutions and learned societies provide a more 
integrated approach than short stand-alone courses.
Actions
Even small-scale funding of, for example, undergraduate 
modules by British Pharmacological Society helps the 
providers of those modules to validate and justify them 
to obtain and maintain institutional support for them. 
This is therefore an area where even limited resources can 
secure the future of undergraduate modules containing in 
vivo education and training. 
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The British Pharmacological Society should continue to 
provide funding for undergraduate education modules, 
basing its support on the adoption and outcomes of the 
rest of the recommendations relevant to undergraduate 
education outlined in this report.
RECOMMENDATION 4:  
CREATE INNOVATIVE RESOURCES 
AND APPROACHES
The community of educators and educational 
institutions should cooperate towards developing 
innovative education and training resources and 
approaches to prepare students for postgraduate 
research and/or employment. These approaches and 
resources should be developed in alignment with 
agreed learning outcomes and set up with impact 
assessment in mind.
Contexts
The Master’s degrees supported by the IPF were highly 
valued by staff and students. Stand-alone Master’s 
degrees are now difficult for institutions to support, in 
part because of the policies of funding councils. The 
importance of a good grounding in knowledge and skills 
pertaining to in vivo research ahead of PhD research or 
entry into employment in industry was recognised.
Actions
The development of new educational and training 
approaches should be approached alongside 
the formation of learning objectives outlined in 
Recommendation 1 and in the light of the evaluative work 
suggested in Recommendation 2. 
Learned and professional societies such as the British 
Pharmacological Society should leverage contacts to 
establish focus groups for employers and research groups 
centred on key in vivo skills areas in order to understand 
where innovative resources are most needed, and how 
they could be used. 
Higher education institutions should establish faculty-
based industrial advisory boards to advise on course 
content, required skills and course design.
There are potential alternatives, such as the development 
of distance e-learning. Such courses could help students 
understand key principles and equip them for entry to 
further study or employment in industry.
RECOMMENDATION 5:  
NURTURE NETWORKS OF GOOD 
PRACTICE
The in vivo sciences cross a range of disciplines, and 
networks of good practice should be cross-cutting 
but deal with specific areas of need: 
  Higher education institutions, employers and 
learned societies should build and/or encourage 
participation in in vivo research and education 
networks, signposting them to people first as 
undergraduates and then throughout their 
careers. 
  Higher education institutions, learned societies 
and other relevant organisations should 
encourage and support the development of 
online open access repositories to collect and 
showcase course materials that use innovative 
approaches to learning in the in vivo sciences. 
  National knowledge-sharing networks sharing 
good practice to advance excellent research with 
high welfare standards should be maintained 
and developed by the research community. This 
should be aided by individual higher education 
institutions, networks of and between named 
persons and other relevant individuals, the 
NC3Rs and learned and professional societies. 
  Learned societies and partners should make 
grants available to support PhD students 
learning a particular in vivo technique in another 
laboratory.
Contexts
There were strong networks fostered at the level of 
individual IMB centres within institutions. Deliberate and 
successful attempts were made to create communities 
of Master’s and PhD students trained within IMB 
centres. The IPF-supported Master’s courses were good 
at exposing students to a wide range of people from 
academia and industry, which provided them with the 
knowledge of potential future sources of information, 
assistance and collaboration, as well as an awareness of 
the range of activities for which in vivo skills and research 
is relevant. 
On the national level, however, networks of knowledge-
sharing and dissemination of good practice were weaker. 
The information to enable researchers to improve aspects 
of their research practice exists, but it is not always 
available to, or targeted at, the right people. Academic 
researchers voiced concerns that the dissemination of 
good practice concerning animal welfare and the 3Rs 
was not sufficiently well-targeted, but rather was placed 
in forums (such as journals and conferences) that were 
not consulted or attended by academic researchers, but 
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rather by technical staff. The targeted dissemination 
of information by NIOs to researchers and the informal 
network of NIOs were cited as examples of effective 
dissemination and communication of current good 
practice. In response to a question asking interviewees 
about potential uses for small pots of money, several 
respondents volunteered the suggestion that grants  
with the aim of ensuring that PhD students are able to 
learn techniques from those who exhibit the current  
good practice for a particular technique would be 
particularly valuable. 
During the course of the evaluation, educators and 
trainers reported innovative and effective approaches 
to undergraduate and postgraduate education and 
training. The means for sharing of these resources are 
currently limited. Additionally, the increasing importance 
of lifelong learning and Continuing Professional 
Development heightens demand for education and 
training resources targeted towards researchers as well 
as students. 
Actions
University departments should develop links with 
relevant people and organisations encompassing a 
variety of areas of work and research in which in vivo 
skills are used. Through these links, speakers should be 
invited to address undergraduates (certainly Level 6, but 
preferably also prior to a placement year). Additionally, 
site visits should be encouraged, and the British 
Pharmacological Society and other organisations that 
can provide links and support may have a role to play in 
establishing these. 
Case studies should be developed, for example by the 
British Pharmacological Society, other learned societies 
and higher education institutions, to support students 
entering into networks of collaboration and knowledge 
and good practice-sharing. 
The British Pharmacological Society and other learned 
and professional societies should invite relevant 
academic departments known for expertise in particular 
techniques to develop short course training in those 
specific techniques, in which people are posted into 
expert labs with some attached funding. Grants can be 
provided on the basis of partnership funding between 
learned societies, academic institutions, and possibly 
research councils, to support PhD students learning 
a particular technique in another laboratory, and 
then returning to their home laboratory to set up the 
technique and to train others. 
Educators should be encouraged to submit some of 
their course materials that use innovative approaches 
(such as ways of teaching statistics) to online platforms. 
The British Pharmacological Society should work 
collaboratively with researchers and educators in higher 
education institutions to ensure that they receive the 
proper support and encouragement to deposit resources. 
Examples of repositories are provided in the box to the 
right. The British Pharmacological Society may wish to 
look at how it could host and disseminate resources that 
are particular to pharmacology education and training. 
Educators and trainers should be directed (for instance, 
by hyperlinks from the British Pharmacological Society 
website) towards the repositories most appropriate to the 
resources they wish to deposit, and a robust ecosystem 
of these repositories should be developed and sustained. 
Proper curation would have financial implications, and 
so the in vivo community could look into a consortium 
approach. For any repository in the ecosystem, the 
consortium should ensure that procedures are in place to 
properly vet uploaded resources.
Resources should be 
deposited with re-use and 
adaptation in mind, so that 
educators and trainers 
can take and adapt what 
they need for their own 
purposes. They should 
therefore be modular in 
construction, and enable 
the extraction of particular 
parts and re-incorporation 
into new resources. The 
resources should be 
accompanied by guidance 
notes. 
Whereas previously issues 
concerning the ownership 
of resources made sharing 
between institutions 
problematic, new methods 
of assessment such as 
the Teaching Excellence 
Framework are likely to 
incentivise sharing, as 
this could be used to show impact. It will be important to 
understand intellectual property requirements to ensure 
that the community is appropriately rewarded for their 
engagement. 
The British Pharmacological Society and other learned 
societies, the Institute of Animal Technology (IAT), the 
Laboratory Animal Science Association (LASA) and animal 
welfare organisations should support the organisation 
of informal events on a regular basis bringing together 
in vivo researchers, animal technologists and others 
interested in animal welfare, to enable colleagues to 
converse, establish contacts, exchange ideas, form 
collaborations, and also develop support networks.
Institutions should encourage the nomination of named 
statistical and experimental design consultants within 
relevant departments or schools, to provide advice on 
licence applications, experimental design, statistics and 
power calculations, with suitable compensation within 
workload allocation models. A national support network 
and training should be provided for these in-house 
consultants.
For conferences run by learned societies, papers dealing 
with good practice, especially concerning the 3Rs and 
animal welfare, should be explicitly included in the 
call for abstracts, and included as part of symposia for 
related research with well-briefed chairs. The British 
Pharmacological Society could produce guidelines to 
inform chairs. Researchers that participated in the IPF 
Examples of repositories 
of free, open access 
e-learning resources:
ETRIS (Educational and 
Training Resources in In 
vivo Sciences):  
www.etris.leeds.ac.uk
OER Commons (Open 
Educational Resources): 
www.oercommons.org
LifesciTRC (Life Science 
Teaching Resource 
Community):  
www.lifescitrc.org
Merlot (Multimedia 
Educational Resource 
for Learning and Online 
Teaching): www.merlot.
org/merlot/index.htm 
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evaluation have a variety of different research areas 
and approaches, and therefore what constitutes good 
practice cannot simply be stipulated across all in vivo 
pharmacology. Even if it could, a separate session dealing 
with good practice may not be the most effective way 
of ensuring its dissemination, as opposed to papers 
integrated into sessions themed by research area. This 
approach to conference organisation is allied to the 
current drive for documenting experimental design 
deriving from the open science movement and the push 
for more detailed reporting of research in response 
to criticisms of research practice and reporting in the 
biomedical sciences. 
To add to existing Continuing Professional Development 
initiatives, residential workshops should be established 
to bring scientists together who are using a specific 
technique to develop current good practice. At these 
residential workshops, experts would demonstrate the 
technique, and scientists could discuss the challenges 
and limitations of that technique and possibly try it out 
on cadavers. An online database of technique workshops 
should be established, and this should be part of an in vivo 
skills training and dissemination network established in 
partnership between learned and professional societies, 
research councils, industry and representatives from 
higher education institutions. 
The British Pharmacological Society and other learned 
societies should encourage greater sharing of good 
practice and training resources through open access 
repositories, and regularly draw members’ attention 
to the repositories in general, as well as any items that 
might be specifically relevant to their research. This 
would not require the British Pharmacological Society 
to act as a curator for these resources, but to coordinate 
their dissemination. 
The British Pharmacological Society and other learned 
societies should introduce dedicated prizes for models of 
good practice, which would encourage submissions and 
dissemination of these models. 
The British Pharmacological Society should raise the 
profile of prizes such as the Drug Discovery of the Year 
Award, and use it as a source of examples and learning 
resources.
RECOMMENDATION 6:  
PROVIDE SUPPORT FOR EARLY 
CAREER RESEARCHERS 
  Learned societies and partners should make 
a new strategic commitment to fund pump-
priming grants for early career researchers. Such 
grants would support the development of new 
or adapted animal models and techniques to 
advance standards of animal welfare, the 3Rs, 
make research more potentially translatable, 
and provide data that recipients can use to apply 
for further grants.
  Higher education institutions, research councils, 
learned and professional societies should 
recognise the importance of explicitly in vivo 
research fellowships, and should work together 
to ensure that these positions can be financially 
supported and sustained.
Contexts 
Support for early career researchers is vital to their career 
development, and the maintenance and development 
of in vivo education, training and research capability and 
capacity. Pump-priming grants were relatively small 
sums of money that allowed holders to develop and use 
new models, in one case with the effect of being able to 
form a collaboration that has led to the awarding of a 
fellowship and a permanent lectureship. Fellowships have 
been praised by those who held them for giving them the 
security and freedom to conduct research. 
Actions
Pump-priming grants are useful to fund small projects 
and specific initiatives, in particular for early-career 
researchers, as this work may enable them to successfully 
apply for larger grants, particularly to open up new areas 
of research and improve current practice, for instance 
by pioneering a refinement to an established animal 
model of disease. There may be several mechanisms 
to guarantee pump-priming grants. Higher education 
institutions could play a role, and innovative ways of 
funding should be explored, such as those used by 
drug discovery groups within academia. The British 
Pharmacological Society and other learned societies 
should contribute to efforts to fund these grants. Awards 
may be made conditional on institutional sign up to the 
Concordat on Openness on Animal Research, and the 
effective dissemination of the new techniques developed 
or 3Rs improvements. 
The fellowship stage is most in need of intervention. 
While organisations such as the British Pharmacological 
Society are not in a position to fund fellowships 
themselves, they are in a position to communicate their 
value to career development and research capability. A 
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partnership approach may be able to leverage enough 
funds from other commercial partners and funding 
bodies to secure explicitly in vivo research fellowships in 
or across institutions. 
Research councils, learned and professional societies and 
higher education institutions should explore and advance 
ways in which the supportive environment experienced 
by the fellows appointed with support from the IPF can be 
extended to all academic researchers, from early career 
onwards. This may involve valuing their work in a more 
multi-dimensional way, and acknowledging their broader 
contribution to research, education, training and public 
engagement (see Recommendation 10). 
RECOMMENDATION 7:  
SUPPORT INTEGRATED PATHWAYS 
FOR TECHNICIANS AND ANIMAL 
TECHNOLOGISTS 
There should be strong institutional support for 
career progression, skills training and job security 
for technicians and animal technologists, which 
takes account of their key roles in laboratory animal 
research. Laboratory animal technologists should 
be more integrated into the planning and conduct 
of academic research and preclinical research 
and development, both in industry and academic 
research.
Contexts 
Researchers have noted several benefits of having 
technicians and animal technologists, which include 
performing procedures, allowing research to continue 
in the absence of the PI, contributing to undergraduate 
education, training of researchers and postgraduates, 
and providing stability and continuity of skills. There 
is considerable concern that funding to appoint and 
retain technicians is insufficient. Increased integration 
of laboratory animal technologists into academic 
research will allow academic researchers to make use of 
their expertise in husbandry, welfare and other aspects 
of practical experimental design and the conduct of 
experiments, as well as enhance the status and visibility 
of these individuals in their institutions, which would 
increase the likelihood of core funding for their position. 
There is evidence of this occurring in industry, but to a 
lesser extent in academic research. 
Actions
The British Pharmacological Society should constructively 
participate in BBSRC, MRC and Science Council work on 
animal technologists and technical skills, alongside the 
IAT, LASA, Establishment Licence Holders, NTCOs and 
NACWOs. In particular, there is a need for a technical/
technologist career pathway to ensure that skills 
are retained through the long-term employment of 
technicians and animal technologists, and that there 
is increased employment of permanent research 
infrastructure technicians.
The British Pharmacological Society and other learned 
societies should improve their offer for technical 
members, especially those working with animal welfare 
organisations. Spaces should be opened to enable these 
people to present at annual meetings, network, and 
highlight their role in institutions as part of the mission of 
‘creating strong research communities’.
Institutions should consider appointing someone 
with practical in vivo skills experience analogous to 
the Experimental Officer appointed as a postdoctoral 
research associate to the IMB centre at The University 
of Manchester, to the roles of NTCO and/or NIO, to 
perform or oversee similar functions such as: serving as 
a repository of in vivo skills and current good practice; 
delivering training and judging competency; ensuring 
that knowledge of current good practice is disseminated 
to the appropriate people; and, possibly, acting as an 
introducer to break down barriers between academic 
researchers and those in clinical or industry roles. The 
position or positions should not be restricted to one 
faculty or school, and should receive full institutional 
support.
The British Pharmacological Society needs to find new 
ways of collaborating with organisations such as the IAT 
and LASA to secure and advance the role of laboratory 
animal technologists in the research effort, both in higher 
education institutions and industry, including SMEs. This 
may include the establishment of a joint working group, 
associate membership of the British Pharmacological 
Society for IAT or LASA members, or cooperation around 
some of the initiatives proposed in this report. One 
common goal for the British Pharmacological Society, IAT 
and animal welfare organisations is to improve the welfare 
of laboratory animals, which in turn will reduce their 
suffering and lead to better and more reproducible data.
Higher education institutions should implement those 
sections of the Brown Report22 that stipulate that 
senior laboratory animal technologists should be fully 
integrated with researchers and into research teams, 
and be given significant input into both the design and 
implementation stages of research projects. 
Higher education institutions should consider adopting 
the industry practice of laboratory animal sciences units, 
which undertake all in vivo research regardless of the 
research area. 
Animal welfare organisations and institutions such as the 
NC3Rs, the IAT and LASA also have a role in developing 
in vivo skills. They should support and participate in any 
initiatives to develop laboratory animal technologists 
and the technical capabilities of academic research 
institutions and industry.
22 The Brown Report (2013) Independent Investigation into Animal 
Research at Imperial College London. Available online at: http://
brownreport.info/wp-content/uploads/2014/02/The-Brown-Report.pdf
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RECOMMENDATION 8:  
ESTABLISH APPRENTICESHIPS FOR 
IN VIVO SCIENCES
Higher education institutions, the British 
Pharmacological Society, the ABPI, and industrial 
and clinical partners should collaborate in the 
development of pharmacology apprenticeships, 
including degree apprenticeships.
Contexts 
The advent of degree apprenticeships was thought by 
stakeholder workshop participants to be a potential 
opportunity for the development of in vivo skills in the 
UK. Apprenticeships were cited as a way to help to break 
down the dichotomy between animal technologists and 
researchers, and provide an alternative pathway for skills 
training and the development of in vivo expertise. 
Actions
A collaborative approach towards the development 
and validation of apprenticeships, including degree 
apprenticeships, between organisations such as the 
British Pharmacological Society, the IAT, LASA, higher 
education institutions, the ABPI and industry along the 
lines of the IPF initiative should be pursued to help ensure 
that high quality programmes are developed which meet 
the needs of various stakeholders.
RECOMMENDATION 9:  
FOSTER COLLABORATIONS ACROSS 
ACADEMIA, INDUSTRY AND THE NHS
Research collaborations involving in vivo researchers 
in academia, industry and the NHS need to be 
supported, with obstacles to cooperation identified 
and addressed. Academics, higher education 
institutions and industry should work together, 
supported where appropriate by research councils 
and learned and professional societies, to conduct 
studies and evaluations to inform and facilitate 
long-term links, collaborations and relationships 
between academic education, training and research, 
industry and the NHS. 
Contexts
Existing initiatives such as CASE PhD studentships and 
BBSRC Industrial Partnerships as well as fellowships 
exist to foster and support collaborations. Concerns 
have been expressed, however, in particular at the 
stakeholder workshop, that certain barriers or obstacles 
are preventing more successful collaboration between 
academics and industry. Some of the main problems are 
the cost of formal collaborations such as the funding 
of PhD studentships, different priorities and ways of 
working, and a lack of understanding on the part of 
academic researchers 
as to the benefits of 
collaboration with 
industry. The IMB centres 
at The University of 
Manchester and King’s 
College London had 
qualified success in forging 
collaborations between 
academic researchers 
and industry, in which 
a responsible member 
of staff was a vital 
component. The role of 
industry liaison is now a 
more common one in UK 
universities. 
In a number of cases, 
collaboration between 
academic researchers and 
industry does not bear fruit 
immediately. It may take 
time for understanding of 
what each party can offer 
the other, and what they 
need from the interaction, 
to develop. An example 
of this is the relationship 
between the University 
of Leeds and the CRO 
Covance, which is detailed 
in the box to the right. 
Actions
Models of lowering costs of industry-academia 
collaboration should be developed, taking inspiration 
from schemes such as ‘Find Your Ideal Partner’ at King’s 
College London, and the Industry Impact Fellowship at 
the same institution. 
There is a role for the British Pharmacological Society in 
promoting networking between academics and industry, 
and fostering potential collaborations. The British 
Pharmacological Society or alternative organisations 
have the potential to act as an introducer and facilitator, 
and can also provide training to academic researchers on 
how to manage networking opportunities, including the 
use of social media websites such as LinkedIn, to develop 
contacts with people in industry. 
As a minimum, the British Pharmacological Society and 
other learned societies should produce information 
documents in collaboration with some university industry 
liaison officers to address key questions and concerns 
that academics might have, such as those relating to 
intellectual property, costs, publications, REF impact, 
and setting up partnerships.
Example of an academic –  
industry collaborations 
for in vivo education:
Covance, a CRO, has 
contributed to the 
design and delivery 
of Level 5 and Level 6 
undergraduate education 
modules in Drug 
Discovery, Toxicology, 
and In Vivo Pharmacology 
at the University of Leeds 
for over seven years. 
Recently, they have 
identified a shortage of 
individuals equipped with 
the knowledge, skills and 
expertise to undertake 
biopharmaceutical 
research. 
To address this skills gap, 
they are working with 
the Faculty of Biological 
Sciences at the University 
of University of Leeds to 
develop and co-deliver 
an MSc programme in 
Biopharmaceuticals, both 
for their own employees 
and the sector as a whole.
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Researchers in academia should be made better aware of 
the benefits of industrial collaboration, for example the 
access to drugs, facilities, and animal models. One way 
of doing this could be to provide a session at the annual 
British Pharmacological Society meeting, Pharmacology. 
This awareness of the importance of mutual benefits 
is particularly important where and when higher 
education institutions do not value the outputs of such 
collaborations. 
Named individuals should be identified within universities 
and research institutes to broker connections between 
industry, clinicians and researchers. They should act 
as connectors, facilitating and fostering translational 
research collaborations. 
The value of events to bring together people from 
academia and industry need to be shared and encouraged 
in universities and research institutes. Discussions 
between academics and researchers from industry centred 
on challenges and solving particular problems has the 
potential to make academic researchers more aware of the 
kind of data valued by industry, and industry more aware 
of the challenges faced by academic researchers, and the 
potential support they can therefore offer them. 
There is a role for organisations such as the British 
Pharmacological Society, in collaboration with other 
learned societies, companies and industry bodies, to 
establish the means by which sabbaticals in industry might 
be established and made into a normalised part of academic 
careers. The advantage of sabbaticals such as these 
would be to give academic researchers, including but not 
restricted to those who work with in vivo models, exposure 
to the rationales, working practices and needs of industry.
There is a need for industry bodies to support and 
enable CROs and SMEs to take undergraduate students 
on placement, and ensure that they can provide a high 
quality placement. As CROs and SMEs do not necessarily 
have the temporal horizons or institutional means 
to commit to long-term placements, alternative 
placement models with different timescales will need 
to be explored. The British Pharmacological Society, in 
conjunction with other learned societies, industry bodies 
and higher education institutions (especially placement 
officers), can work to produce guidance to CROs and SMEs 
on placements, and how they can get the best out of 
students placed with them.
The ABPI should be invited to audit the proportion of 
studentships, project grants and industry placements 
that go to genuinely in vivo work. In future data-gathering 
and reporting, organisations such as the ABPI, research 
councils and learned societies need to identify more fine-
grained categories of researcher and skills, to ensure that a 
more precise picture of skills needs and gaps is generated.
On the part of higher education institutions, academic 
researchers and industry, alternative means of 
collaboration and the different ways in which 
collaborations develop should be recognised. Case 
studies should be published on the different ways in 
which long-term collaborations develop. 
More research on modes and pathways of collaboration 
in pharmacology needs to be conducted by social 
scientists, and disseminated to the relevant scientific 
and policy communities. A collaborative approach should 
be adopted to the development of research questions 
incorporating scholars from the humanities, social 
sciences, scientists from academia and industry, and 
clinicians. A possible model for this is the approach is 
the interdisciplinary group convened to deliberate on 
an agenda for humanities and social science research on 
laboratory animal science and welfare.23 
RECOMMENDATION 10:  
RECOGNISE AND SUPPORT 
ENGAGEMENT WORK 
Public engagement and student outreach 
should be supported and encouraged by higher 
education institutions and learned societies as a 
core activity of academic researchers, advancing 
the commitments contained in the Concordat on 
Openness on Animal Research.
Contexts 
Public engagement activities were regarded positively by 
those who participated in them. They are a useful source 
of ideas and reflection for the researchers themselves, 
and for 3Rs improvements. Public engagement is now a 
major responsibility of institutions who have signed up to 
the Concordat on Openness on Animal Research and the 
individuals who work within those institutions.
Actions
Higher education institutions should ensure that 
researchers are provided with the time and resources, 
(including administrative support), to plan, conduct, 
and evaluate public engagement activities. In part this 
requires a shift from valuing people based on narrow 
metrics based on first/last author credits and towards 
valuing the overall contribution and role of individuals in 
their own institutions and communities of educators and 
researchers. 
Learned societies such as the British Pharmacological 
Society should ensure that researchers receive advice and 
mentoring to engage in productive public engagement.
Researchers should ensure that public engagement involves 
a commitment to two-way dialogue with lay persons.
Institutional press releases regarding research in which 
in vivo research has played a part should mention that 
animals were involved, in line with the content guidelines 
published by the Concordat on Openness on Animal 
Research, which has to date been signed by representatives 
of over 100 organisations and institutions.24
23 Davies GF et al (2016) Developing a Collaborative Agenda for 
Humanities and Social Scientific Research on Laboratory Animal Science 
and Welfare, PLoS One, Vol. 11 No. 7: e0158791.
24 See http://www.understandinganimalresearch.org.uk/policy/
concordat-openness-animal-research/signatories-to-the-concordat-on-
openness-on-animal-research
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Concordat on Openness on Animal Research  
Headline commitments:
“We will be clear about when, how and why we use animals in research.” 
This includes a key commitment that “When we communicate about the use of animals in research, we 
should provide accurate descriptions of the benefits, harms and limitations of such research, be realistic 
about the potential outputs of such research, and be open about its impact on animal welfare and the ethical 
considerations involved.”
“We will enhance our communications with the media and the public about our research using animals.”
“We will be proactive in providing opportunities for the public to find out about research using animals.”
www.understandinganimalresearch.org.uk/policy/concordat-openness-animal-research
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APPENDICES
APPENDIX 1 –  
THE STEERING COMMITTEES
IPF steering committee:
Mike Collis (Pfizer and Chair)
Malcolm Skingle (GSK)
Martin Todd (AstraZeneca) 
Sue Brain (British Pharmacological Society)
With additional input from David Tattersall and Rebecca 
Dias (both Pfizer)
IMB centre steering committee:
Aileen Allsop (Independent Chair)
Mike Collis (British Pharmacological Society and project 
co-ordinator)
Susan Fleetwood-Walker (University of Edinburgh)
Kevin Fox (Cardiff University)
Stephen Holgate (University of Southampton)
Malcolm Skingle (GSK)
Graeme Smith (AstraZeneca) 
Funder representatives 
Stuart Fancey (Assistant Director of Research and 
Innovation, SFC)
Kimberley Hackett (Higher Education Policy Adviser, 
HEFCE)
Simon Kerley (Strategy and Policy Manager, BBSRC)
David McAllister (Head of Skills and Careers, BBSRC)
Andrew Staphnil (Business Interface Manager, BBSRC)
Harriet Warburton (Programme Manager, Research 
Careers Awards, MRC)
Stephanie Williams-Blackwell (Strategy and Policy 
Officer, BBSRC)
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APPENDIX 2 –  
LIST OF ACRONYMS
3Rs   Replacement, Reduction and Refinement of 
the use of animals in research
ABPI   Association of the British Pharmaceutical 
Industry
A(SP)A  Animals (Scientific Procedures) Act 1986
BBSRC  Biotechnology and Biological Sciences 
Research Council
BHF   British Heart Foundation
CASE   Collaborative Awards in Science and 
Engineering 
CRO Contract Research Organisation
CRUK   Cancer Research UK
DTP   Doctoral Training Partnership
EDA  Experimental Design Assistant
GSK GlaxoSmithKline
HEFCE   Higher Education Funding Council for England
HESA   Higher Education Statistics Agency
IAT   Institute of Animal Technology
IMB   Integrative Mammalian Biology
IPF   Integrative Pharmacology Fund
LASA   Laboratory Animal Science Association
LAVA   Laboratory Animals Veterinary Association
  
MRC   Medical Research Council
NACWO  Named Animal Care and Welfare Officer
NC3Rs   National Centre for the 3Rs
NCO  Named Compliance Officer
NIO   Named Information Officer
NTCO   Named Training and Competency Officer
NVS  Named Veterinary Surgeon 
OLS   Office for Life Sciences 
PI  Principal investigator
PIL   Personal licence 
RCUK   Research Councils UK
REF Research Excellence Framework
SFC   Scottish Funding Council
SME  Small to Medium sized Enterprise
STEM   Science, Technology, Engineering and 
Mathematics
UAR  Understanding Animal Research
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